Psychoactive substances present in "legal highs" acquired in "smartshops" or via internet by Ana Margarida Carvalho Araújo
 
 
 
 
 
 
 
 
 
 
 
 
 
Ana Margarida Carvalho Araújo 
 
Master Degree in Forensic Sciences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
University of Porto 
 
September 2013 
Supervisors 
 
Doutora Paula Guedes de Pinho 
Professor Doutor Félix Carvalho 
Professora Doutora Maria de Lourdes Bastos 
Psychoactive substances present in “legal highs” 
acquired in “smartshops” or via Internet 
 
Chemical characterization and in vitro cytotoxicity studies 
of synthetic cathinones 
 
 
II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental work carried out in REQUIMTE Laboratory, Department of Toxicology,  
Faculty of Pharmacy, University of Porto 
 
 
 
III 
ACKNOLEDGMENTS 
Agradecimentos 
 
A vida é feita de sonhos e desafios, uns mais fáceis de concretizar, outros nem tanto. Contudo, 
com dedicação e apoio tudo é possível! Este projeto resume-se a mais um desafio que eu impus a 
mim mesma na minha ainda curta carreira científica. Posto isto, não poderia deixar passar em 
branco o apoio, direto ou indireto, de todas as pessoas que tornaram este desafio possível. Assim, 
gostaria de agradecer...  
 
 À comissão coordenadora do Mestrado em Ciências Forenses, em especial à Professora 
Doutora Teresa Magalhães pela criação e orientação do mesmo e pela oportunidade de 
frequentar um Curso que tanto almejava, permitindo-me realizar o trabalho numa área 
que me dá tanto gosto. 
 
 À Doutora Paula Guedes de Pinho, orientadora deste trabalho não apenas pelos 
ensinamentos, mas sobretudo pela confiança, incentivo, conselhos, paciência e amizade. 
Tudo isso me ajudou a tornar-me numa pessoa mais descontraída e segura de mim. 
Agradecer ainda por me aceitar e acompanhar nesta jornada, mesmo que ao início não 
fosse a minha área de conforto. Espero ter estado à altura! 
 
 Ao Professor Doutor Félix Carvalho pela coorientação deste trabalho. Pela inspiração e 
confiança que me transmite. Pelos elogios que me deram vontade em ir mais além, em ser 
melhor...não sei se correspondi às expectativas, mas juro que tentei. 
 
 À Professora Doutora Maria de Lourdes Bastos em primeiro lugar por me ter dado a 
oportunidade de poder integrar esta maravilhosa equipa e ter depositado essa confiança 
em mim. Espero também não a ter decepcionado. Obrigada ainda por ter coorientado este 
trabalho e pelas carinhosas palavras de incentivo. 
 
 À Professora Doutora Márcia Carvalho pelo incansável apoio e ajuda no isolamento de 
hepatócitos e ensaios afins. Obrigada por todo o tempo disponibilizado, dedicação e 
ensinamentos...pela boa disposição e serenidade.  
 
 À Doutora Helena Gaspar pela colaboração neste trabalho, nomeadamente na realização 
de todas as análises de RMN. Obrigada pela disponibilidade e prontidão em esclarecer as 
minhas dúvidas. 
 
 
IV 
 À Doutora Ana Cardoso Matias um obrigada igualmente pela colaboração. 
 
 A todos os meus colegas e restantes colaboradores do Departamento de Toxicologia  da 
Faculdade de Farmácia da Universidade do Porto por tornarem a integração mais fácil. 
Obrigada pelos rebuçadinhos que adoçaram os meus dias mais longos, pelos bolos de 
aniversário e almoços em “família”, pelas cantorias desafinadas de alguns e outros 
momentos afins...A todos agradeço a forma amiga como me receberam. 
 
 Um obrigada especial à Márcia sempre pronta a dar-me uma mãozinha quando precisei, à 
Maria João pelos ensinamentos e apoio incondicional na última etapa do trabalho e à 
Diana pela ajuda estatística final.  
 
 À pequena Mariana por todas as horas de brincadeira e gargalhadas contagiantes que me 
ajudaram a fazer uma pausa do trabalho e abstrair das preocupações. 
 
 Ao Rui por me ajudar a pôr em prática as minhas ideias criativas, apesar de adorar ser 
sempre do contra e deixar-me uma pilha de nervos por deixar tudo para a última da hora. 
 
 À restante “família emprestada” por me aturar em todos os momentos. 
 
 À minha família, em especial à minha mãe e às minha irmãs...espero que se orgulhem de 
mim! Obrigada por me terem dado ânimo nos momentos em que desanimei, por me terem 
ensinado a nunca parar, a lutar sempre pelo que quero, por todos os valores que me 
transmitiram...por serem da maneira que são...especiais! 
 
 Por último mas o elemento mais importante de toda esta jornada e outras tantas que já 
passei: OBRIGADA PEDRO! Obrigada pela grande/enorme/gigante paciência, por todo o 
amor e apoio e por nunca teres duvidado das minhas capacidades. Obrigada por 
acreditares sempre em mim, e por me ajudares a ser sempre melhor! 
 
 
Por tudo isto e muitas outras coisas... 
Obrigada a todos! 
 
 
 
 
 
V 
CONGRESS PRESENTATIONS 
 
 
The results described in this dissertation were presented in a scientific meeting (49th 
Congress of the European Societies of Toxicology; Interlaken; Switzerland; 1 – 4 September 
2013) as a poster communication (image below). The list of the submitted abstract is presented: 
 
 Araújo, Ana Margarida; Bastos, Maria de Lourdes; Carvalho, Márcia; Carvalho, 
Félix; Gaspar, Helena; Cardoso Matias, Ana; Guedes de Pinho, Paula. (2013) 
Identification of psychoactive substances in “legal highs” marketed in Portugal. 
Toxicology Letters, Abstracts. 221S: S59-S256.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VII 
ABSTRACT 
 
The world’s culture on recreational drugs has recently changed and the consumption of 
new psychoactive substances, known as "legal highs", is continuously growing, especially among 
young people. These drugs are typically sold via Internet or "smartshops" as legal alternatives 
to controlled substances, being announced as “bath salts” and “plant feeders” and claiming to be 
not intended for human consumption. The astonishing speed at which these compounds appear 
makes detection, identification and the associated health risks and potential harm difficult. 
Information about the actual content of these products is still very scarce, raising concern of 
consumer safety. Although the illusion of being substances more pure and safe for consumption, 
the number of fatalities has increased, with clinical patterns comparable to those reported for 
better-studied stimulant drugs like amphetamines. 
The purpose of this study is to chemically characterize commercial products marketed 
as “plant feeders” in Portuguese “smartshops”, using highly powerful methodologies, such as 
GC-MS (Gas Chromatography coupled to Mass Spectrometry) and NMR (Nuclear Magnetic 
Resonance) analysis. It is intended to further evaluate the hepatotoxic effects of two commercial 
“legal high” products and individual cathinone derivatives, using HepaRG cells and primary rat 
hepatocytes cultures as in vitro models. 
NMR spectroscopy, the most useful analytical technique for determining the structure of 
molecules, in combination with the highly sensitive analytical methodology GC-MS were applied 
to unveil the real composition of these products. The main active compounds identified in 
methanolic solutions of the marked products are synthetic cathinones, namely methedrone, 
methylone, buphedrone, flephedrone, pentedrone, 4-methylethylcathinone (4-MEC), 
ethcathinone, methylenedioxypyrovalerone (MDPV), but also aminoalkyl benzofurans 
derivatives, cocaine analogs (dimethocaine) and caffeine. The content differs between the 
products; some containing only one active compound, while others have a greater variety. 
Qualitative and quantitative variability was found between identical products sold in different 
“smartshops”. 
In cytotoxicity studies, cells were exposed to the test drugs (0.05 – 5mM), at 37°C for 48 
hours. MDMA was used as a reference for comparison effects. Results show that for all agents 
tested there is an increase of cell death dependent of chemical concentration. In both cell 
models, methylone proved to be the least hepatotoxic individual agent and MDPV the most 
potent. The commercial “legal highs” studied ("Bloom" and "Blow") induced a severe 
hepatotoxicity, with EC50 values significantly lower or equal to MDMA, respectively.  
Mathematical models of independent action (IA) and concentration addition (CA) were applied 
for modeling the expected effects of “legal highs” mixtures; the exposure of primary hepatocytes 
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to “Bloom” shows an obvious synergism, while “Blow” reveals an additive effects. Primary rat 
hepatocytes showed to be more sensitive for hepatotoxicity evaluation since the HepaRG are 
metabolically less competent.  
In synopsis, these results show a miscellany of psychoactive compounds present in 
“legal high” products marketed in Portugal, with hepatotoxic effects extremely pronounced. In 
addition, potential harmful interactions among synthetic cathinones are expected when these 
drugs are taken concomitantly. These data contributes to unveil the health hazards likely to 
arise from exposure to these emerging psychoactive drugs and may influence behavioral 
changes in consumers worldwide. 
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RESUMO 
 
 
A cultura do mundo das drogas recreativas mudou recentemente e o consumo de novas 
substâncias psicoativas, conhecidas como "drogas legais", tem vindo a crescer continuamente, 
especialmente entre os jovens. Estas novas drogas são normalmente vendidas através da 
Internet ou "smartshops" como alternativas legais para substâncias controladas, sendo 
anunciadas como “sais de banho” e “fertilizantes para plantas”, afirmando não serem destinadas 
ao consumo humano. A velocidade estonteante a que estes compostos aparecem torna a sua 
detecção, identificação e avaliação dos riscos de saúde associados e dano potencial difíceis.  
Informações sobre o conteúdo real destes produtos são ainda muito escassas, conduzindo a um 
aumento da preocupação com a segurança dos consumidores. Embora exista a ilusão de serem 
substâncias mais puras e seguras para o consumo, o número de mortes aumentou, com padrões 
clínicos comparáveis aos relatados para drogas estimulantes bem estudadas, como é o caso das 
anfetaminas. 
Um dos objectivos deste estudo passa por caracterizar quimicamente produtos 
comercializados como “fertilizantes para plantas” à venda em “smartshops” portuguesas, 
utilizando metodologias altamente poderosas, tais como a análise por GC-MS (cromatografia 
gasosa acoplada à espectrometria de massa) e RMN (espectroscopia por ressonância magnética 
nuclear). O trabalho destina-se ainda a avaliar os efeitos hepatotóxicos de dois produtos 
comerciais adquiridos em “smartshops” e de derivados de catinonas vendidos como agentes 
individuais através da Internet, usando células HepaRG e cultura primária de hepatócitos de 
rato como modelos in vitro. 
A espectroscopia por RMN, uma técnica analítica útil na determinação da estrutura de 
moléculas, em combinação com uma metodologia analítica altamente sensível, o GC-MS, foram 
aplicadas para desvendar a composição real destes produtos. Os principais compostos ativos 
identificados em soluções metanólicas foram catinonas sintéticas, nomeadamente a metedrona, 
metilona, bufedrona, flefedrona, pentedrona, 4-metiletilcatinona (4-MEC), etcatinona, 
metilenodioxipirovalerona (MDPV), mas também derivados dos aminoalquil benzofuranos, 
análogos da cocaína (dimetocaína) e cafeína. O conteúdo entre os produtos mostrou-se variável; 
alguns contendo apenas um composto ativo, enquanto outros têm uma maior variedade. Foi 
encontrada variabilidade qualitativa e quantitativa entre produtos idênticos vendidos em 
“smartshops” diferentes. 
Nos estudos de citotoxicidade, as células foram expostas a drogas teste (0.05 – 5mM) a 
37˚C, durante um período de incubação de 48h. A MDMA foi usada como composto de referência 
para comparação de efeitos de hepatotoxicidade. Os resultados mostram que para todos os 
agentes testados existe um aumento da morte celular dependente da concentração química. Nos 
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dois modelos celulares, a metilona mostrou-se o agente individual menos hepatotóxico e o 
MDPV o mais potente. As “drogas legais” estudadas (“Bloom” e “Blow”) induziram severa 
hepatotoxicidade, com um valor de EC50 consideravelmente inferior e similar aos da MDMA, 
respectivamente. Modelos matemáticos de ação independente (IA) e adição da concentração 
(CA) foram aplicados para calcular os efeitos expectáveis das misturas de “drogas legais”; a 
exposição dos hepatócitos primários à mistura de “Bloom” mostra um evidente sinergismo, 
enquanto que o “Blow” revela uma situação de aditividade de efeitos. Os hepatócitos primários 
de rato mostraram ser mais sensíveis na avaliação da hepatotoxicidade, uma vez que as HepaRG 
parecem ser metabolicamente menos competentes. 
Em resumo, estes resultados mostram uma miscelânea de compostos psicoativos 
presentes nos produtos de "drogas legais" comercializados em Portugal, com efeitos 
hepatotóxicos muito pronunciados. Mostram ainda a existência de interações potencialmente 
perigosas entre catinonas sintéticas administradas concomitantemente. Esta informação é 
crucial para revelar os riscos para a saúde susceptíveis de resultar da exposição a estas drogas 
psicoativas emergentes, podendo também influenciar mudanças de comportamento de 
consumidores de todo o mundo. 
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In recent years, the world's drug culture has changed substantially and, nowadays, 
includes a group of products known as "legal highs", "legal drugs" or "designer drugs", referring 
to a range of natural or artificial psychotropic substances that are marketed as “incense”, “plant 
feeders” and “bath salts”, although this is not their legitimate practice. These products are 
purchased to be used as recreational drugs that mimic the effects of illegal drugs of abuse, as 
cocaine and 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"), acting as their legal 
alternatives, being easily purchased at Internet or through specialized shops – called 
"smartshops" or "headshops" [1-3]. 
The packages are very attractive with suggestive names – "Bliss", "Bloom", "Blast", 
"Kick" – as a marketing strategy to attract consumers (Figure 1). All packages are labeled as "not 
for human consumption" in order to circumvent the laws that govern the sale of psychoactive 
substances [4-5]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – “Legal highs” sold in Portuguese “smartshops” (Magic mushroom and Euphoria) 
 
 
1.1 The problem of “legal highs” 
 
These new recreational substances are very similar to the controlled drugs in their 
chemical structure and/or pharmacodynamics [6]. The term "legal highs" is defined as 
psychoactive substances whose production, sale and possession, are not covered by the law, not 
being prohibited [7]. This seems to be the ideal situation from the point of view of producers, 
sellers and consumers of these new drugs; however, there are a number of problems associated, 
as will be discussed in this thesis. 
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Despite some legislative initiatives on these products, there are evidences suggesting 
that little has changed. Consequently, banned substances are still being sold under a new guise. 
It is not known how many and which of these products contain substances known as legal or 
illegal substances [5, 8-10]. In addition, new products are also produced through the modification 
of the chemical structure of substances that have been enacted [11-13]. The emergence of these 
new substances is extremely challenging, not only due to the large number of different 
compounds that are theoretically possible to exist, but also due to the number of those that are 
actually manufactured, distributed and consumed [14]. The new alternative products are 
immediately promoted, being the Internet an effective medium for its dissemination, once it 
responds quickly to legal changes. Thus, the online market is an important tool to identify the 
new trends of drugs of abuse [15]. In view of this panorama, as the law is always a step behind, 
manufacturers and consumers continue to explore legislative gaps to constantly create new 
"legal drugs", continuing the “cat and mouse game”. 
 
Another problem is that these drugs are sold in packages highly variable and 
inconsistent concerning its content. This has been verified for products with the same brand 
name and identical packages. The variability found refers to significant qualitative as 
quantitative differences. This inconsistency increases the risk of toxicity and injury associated 
with its use. In accordance, the information provided to consumers on the composition, dosage, 
duration and even the effects is generally limited or imprecise [6, 8-9, 16].  
Despite all the problems associated with these new psychoactive substances, its 
popularity keeps growing due to the  illusory idea of security that was installed on a 
misinformed public. In addition, other reasons are associated with their incessant demand, 
where users suggest a decline in purity of illegal drugs, replacing them by these new synthetic 
drugs. These new substances produce similar effects to illicit drugs and are easily purchased, 
but the biggest advantage lies on the absence of criminal sanctions [8, 9, 11, 13]. 
 
In contrast to what happens with traditional drugs of abuse, there is little or no 
information available about these new substances, both in terms of their chemical composition 
and toxicity or long-term effects associated with its use, representing a serious challenge for 
public health authorities [3, 9, 12]. 
Based in medico-legal information, excessive use of drugs of abuse is a social danger 
respecting self-harm and crimes committed under the influence of such substances. The easy 
access to new recreational products lead to great social burden, as exemplified by the 
disruption of personality, mental disorders and deterioration of social relations, leading users to 
a social marginalization [17].  
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The fact that most of these new drugs are legal in many countries, lead many consumers 
to believe they are harmless substances. Unfortunately, the consumption of these unknown 
substances is very risky and many of them appear associated with adverse physical effects and 
fatalities [18-21]. To increase the problem, it is common for consumers to create "designer 
mixtures” in order to enhance its effects, which consequently become unpredictable, making it 
difficult to evaluate the effects of specific substances [17]. 
Hence, it is necessary and urgent for health care providers to be familiar with the effects 
of these new psychoactive substances, as well as it is important that the forensic toxicological 
research community develops strategies for fast and effective recognition of the consumption of 
new "legal highs" [22]. 
For correct application of the law and for benefit of the general community, it is vital 
that a forensic laboratory is able to correctly identify the compounds present in these new 
drugs and determine if the sample is a controlled substance under the legal system of the 
country concerned. The process of detection and identification of new drugs is not easy, because 
many substances exhibit identical chemical, chromatographic and spectral properties, since the 
structural modifications of a controlled substance may include only the addition of a small 
chemical group or the formation of isomeric structures. Furthermore, the absence of standards 
and reference spectra in available bibliotheca data will increase the complexity of identification, 
being hardly achieved through routine analytical protocols. Thus, sophisticated methods of 
analysis are needed to test these unknown products, often through complex and expensive 
processes [6, 11]. 
 
 
1.2 The new drugs evolution 
  
The market of new drugs is characterized by the extreme speed of producers’ reaction 
to the imposition of control measures and monitoring, providing alternatives to banned 
products. According to the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), between 2005 and 2012, more than 230 new psychoactive substances were notified 
through the early warning system (EWS). The rhythm at which these drugs appear on the 
market reached record values in recent years: 24 new substances have emerged in 2009, 41 in 
2010, 49 in 2011 and 73 in 2012 (Figure 2). Currently, about two-thirds of notified substances 
belong to cannabinoids and synthetic cathinones group [23-25]. 
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Figure 2 - New psychoactive substances notified to EMCDDA in 2005-2012 [adapted from 25] 
 
 
 Until 2008, the new psychoactive substances that have emerged in the European Union 
(EU) drug market belong to a restricted number of chemical classes, being the phenethylamines 
and tryptamines the most accounted for [23]. However, the market has undergone drastic 
changes in recent years. The increasing number of substances that has been reported 
corroborates this fact. 
 In the last years, a new chemical class – the synthetic cathinones – with stimulant 
properties emerged in Europe's drug market. These substances are structurally related to 
cathinone, the main natural psychoactive substance of khat plant [26]. In 2010, 15 of the 41 novel 
derivatives detected belonged to synthetic cathinones group, being now the second largest 
family of drugs monitored by EWS [23]. 
 The newly identified substances list also includes a diverse group of plant-derived and 
synthetic substances, including indanes, benzodifuranyls and synthetic derivatives of cocaine, 
ketamine and phencyclidine [6]. 
 
 
1.3 Prevalence 
 
In Europe, studies on the prevalence of use of licit alternatives are scarce and, often, are 
accompanied by methodological limitations such as lack of representative samples [24, 27].  
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During 2008, Polish researchers conducted a study in 1250 students with 18-19 years 
and concluded that 3.5% of these young people had consumed this type of substances at least 
once in their lifetime. In 2010, a follow-up study found an increase to 11.4%. When asked about 
the consumption of licit drugs over the last 12 months, in 2008, 2.6% responded affirmatively 
and this number increased to 7.2% in 2010. This fact can be explained by the exponential 
increase of selling points in Poland, rising from 40 “smartshops” in 2008 to 1500 in 2010 [23]. 
In 2011, a survey was carried out at European countries, including more than 12000 
young people (15-24 years), about their attitudes to the new generation of drugs. The analysis 
of results estimated that 5% of the young surveyed have used "legal highs" (Figure 3). The 
highest percentages came from Ireland (16%), followed by Latvia, Poland and United Kingdom 
(10% each). Italy, Finland and Greece were the countries with the lowest values [28]. 
 
 
 
 
Figure 3 - Percentage of young 
Europeans who consumed, any 
time during life, new licit drugs  
[adapted from 28] 
 
 
 
In the same inquiry, it was asked to young people how they purchased these products. 
The vast majority of respondents (54%) indicated that friends offered them and 36% 
mentioned that they have been obtained at parties. About a third of participants (33%) 
admitted having purchased the substances in specialized shops and only 7% via the Internet 
(Figure 4) [28]. 
 
 
Figure 4 – Market availability of new psychoactive products. [Adapted from 28] 
Other
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After approval of mephedrone control, the British Crime Survey results, obtained from 
2010/2011, showed that in England and Wales, the general population (16-59 years) 
consumed, during this period, the same levels of mephedrone and ecstasy (1.4%). In a more 
restricted age group (16-24), the prevalence increased considerably, equaling the values of 
cocaine powder (4.4%). Note that most of the subjects who reported using mephedrone also 
assume the use of other illicit drugs, in particular cannabis, cocaine or ecstasy. This study also 
shows that men consume about twice more (2%) this type of drugs when compared with 
females (0.8%) [29].  
 
 
1.4 Identification of active components of “legal highs” 
 
The composition of the “legal highs” is one of the problems associated with these 
products, being extremely important and fundamental to know which active compounds are 
present in the different products, for a more effective performance of medical entities. For this 
purpose, analytical procedures should be developed in order to reveal their real composition. 
 
 
1.4.1 Chromatographic techniques 
 
Gas chromatography coupled to mass spectrometry (GC-MS) is an analytical method 
used in most laboratories for qualitative analysis of diverse psychoactive drugs [6, 8, 16, 30-35]. Most 
active components of “legal highs” can be conveniently subjected to analysis and characterized 
by GC due to their low molecular weight [12]. The advantage of this instrumentation is that it is 
relatively inexpensive, can be automated, provides rapid analysis and achieves good resolution, 
sensitivity, specificity and repeatability [36]. 
Another chromatographic technique frequently used is the liquid chromatography (LC) 
that allows the study of substances of higher molecular mass and lower volatility [6-7, 12]. 
These analytical techniques typically use mass spectrometry (MS) as detection 
technique, which allows the identification of interest analytes by characteristic ions resulting 
from molecule fragmentation, being separated according to their mass/charge ratio (m/z) [37]. 
The identification of the interest peaks is accomplished by comparison with spectra libraries 
(e.g. NIST Mass Spectral Library). Unfortunately, the majority of compounds present in "legal 
highs" are not yet referenced in this type of library, which gives a limitation to this technique 
[12]. Different GC and LC methodologies have been extensively used for the qualitative analysis of 
these new commercial products, as summarized in Table 1.
Table 1: Chromatographic techniques used in qualitative analysis of several "legal highs" 
Analytes 
Sample Method 
Stationary Phase 
Mobile Phase Mass 
range 
Reference 
Appearance Preparation Purpose Instrumentation Eluent Program 
Different 
chemical 
classes 
(Cathinones, 
Piperazines, 
other 
substances) 
Over 6000 
powders, 
tablets and 
capsules 
Methanolic extract 
and centrifuged 
Substances 
identification 
GC-MS 
HP-5MS capillary 
column (30m x 
0,25mm x 0,25 µm) 
Helium at flow 
rate of 1mL/min 
50 °C maintained for 
1min., increased 10 
°C/min to 280 °C 
maintained for 10 
min. 
29 to 
600 
amu 
[6] 
Methanol mixed 
with water (1:1, 
v/v) and 
centrifuged 
LC-QTOF-MS 
Ascentis Express 
C18 column (7,5 cm 
x 2,1 mm x 2,7 µm) 
Mixture of 0,1 % 
(v/v) formic acid 
in AcCN and 
water at flow rate 
of 0,3 mL/min 
Gradient mode: 0 
min – 5%, 11 min – 
23%, 15 min – 27%, 
15,2 min – 5%, 21 
min – 5% 
50 to 
1000 
amu 
Different 
chemical 
classes 
(Cathinones, 
Piperazines, 
Tryptamines, 
Canabinnoides 
and other 
substances) 
2094 
samples in 
the form of 
pills, 
tablets, 
gels, 
lollipops, 
powders 
and 
smoking 
mixes 
Ultrasound-
assisted extraction 
with methanol 
Substances 
identification 
LC-QTOF-MS 
Reversed phase 
system using a C18 
column 
0,1 % formic acid 
(A) and 0,1 % 
formic acid in 
acetonitrile (B) 
Linear gradient 
100 
to 
1000 
m/z 
[7] 
Different 
chemical 
classes 
(Cathinones, 
Piperazines 
and other 
substances) 
35 Internet 
and 
headshops 
purchased 
“legal 
highs” 
products 
Methanolic 
extracts (10 
mg/mL) followed 
by centrifugation. 
Supernatants were 
filtered and diluted 
100 times with 
methanol 
Substances 
identification 
Fast GC-MS 
SLB-5MS column 
(10 m x 0,1 mm x 
0,1 µm) 
Helium at 0,5 
mL/min 
100 °C to 270°C at 
50 °C/min and 
maintained for 0,6 
min. 
46 to 
320 
m/z 
[30] 
Different 
chemical 
classes 
(Piperazines, 
Cathinones, 
Caffeine) 
Seven 
samples in 
the form of 
powders 
sold as 
“legal 
highs” 
Methanolic 
extracts (10 
mg/mL) followed 
by centrifugation. 
Supernatants were 
filtered and diluted 
1000 times with 
methanol 
Substances 
identification 
GC-MS 
DB-1MS (30 m x 
0,25 mm x 0,25 µm) 
Helium at 1 
mL/min 
150 °C for 4 min, 
ramp to 350 °C at 32 
°C/min 
40 to 
300 
m/z 
[31] 
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Table 1: Chromatographic techniques used in qualitative analysis of several "legal highs" (continued) 
 
Analytes 
Sample Method 
Stationary Phase 
Mobile Phase Mass 
range 
Reference 
Appearance Preparation Purpose Instrumentation Eluent Program 
Cathinones 
derivatives 
Four 
capsules 
containing 
white 
powders 
Powder was 
extracted into a 
range of solvents 
being injected 
directly. Other 
extracts was 
derivatized with 
PFPA 
Substances 
identification 
GC-MS 
HP-1 capillary column 
(15 m x 0,25 mm x 
0,25 µm) 
Helium at 58 
cm/s 
90 °C for 3 min, 
ramped at 45 °C/min 
to 300 °C, 
maintained for 1 min 
40 to 
450 
m/z 
[32] 
Caffeine and 
other active 
compounds 
Six novel 
psychoactive 
products 
(“legal 
highs”) 
Methanolic extract 
(1mg/mL) 
followed by 
centrifugation. The 
methanolic extract 
was combined 
with a internal 
standard solution 
and MTBE 
Identify the 
active 
ingredients 
and measure 
the caffeine 
content of 
the product 
GC-MS --- --- 
80 °C for 4 min and 
then ramped at 40 
°C/min to 290 °C 
and held for 10,75 
min 
--- [33] 
Cathinones 
and other 
constituents 
Eighteen 
samples 
obtained 
from 
headshops in 
Dublin 
Methanolic extract 
(1mg/mL). The 
mixture was 
sonicated and 
centrifugated 
Substances 
identification 
GC-MS 
HP-5MS column (30 m 
x 0,25 mm x 0,25 µm) 
Helium at 1 
mL/min 
90 °C for 1 min, 15 
°C/min to 280 °C 
and held for 6 min, 
10 °C/min to 300 °C 
maintained for 13,33 
min 
40 to 
800 
m/z 
[34] 
Cathinone 
derivatives 
and other 
constituents 
24 “legal 
highs” 
products 
obtained 
from 18 UK-
based 
websites 
Methanolic extract 
at a concentration 
of 0,50 mg/mL 
Substances 
identification 
GC-(EI/CI)-IT-MS 
Factor four capillary 
column (VF-5 ms) (30 
m x 0,25 mm x 0,25 
µm) 
Helium at 1 
mL/min 
100 °C for 1 min, 20 
°C/min to 280 °C 
and held for 10 min 
40 to 
500 
m/z 
[8, 35] 
Cathinones, 
piperazines 
and caffeine 
Twenty six 
“legal highs” 
purchased 
from five 
different 
Internet sites 
Batches of similar 
tablets were 
assumed to be 
homogenous. 
Methanolic 
extracts 
Substances 
identification 
GC-MS 
SGE solgel capillary 
column (30 m x 0,25 
mm x 0,25 µm) 
--- 
70 °C for 4 min and 
ramping 40 °C /min 
to 280 °C 
40 to 
400 
m/z 
[16] 
1.4.2 Other techniques 
 
Recently, a “test field” as a Raman and Infra-Red spectrometry has been developed for 
the detection and characterization of these new substances, but has only obtained positive 
results for relatively pure substances [9, 14, 38-42]. 
Another technique used in the qualitative analysis of these new substances is nuclear 
magnetic resonance spectroscopy (NMR) [9, 38, 39-40, 43-46]. The existence of a large number of 
positional isomers in synthetic cathinones group requires the use of powerful tools that provide 
structural information to allow differentiation. Still, despite being a powerful tool, the cost 
associated with the NMR technique as well as the necessary technical knowledge, are 
limitations for the application of the NMR technique in routine analysis [47]. 
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2.1 History 
 
Khat (Figure 5) (Family: Celastraceae; Specie: Catha edulis) is a slow growing plant, 
native to Eastern Africa and Arabian Peninsula and has other names and spellings such as kat, 
chat, quat, catha, tschat, miraa, African salad, African tea, Abyssinian tea, kuses-salahin, and 
tohai [48].  
The origin of the plant is controversial. Many believe that its origin is Ethiopian; others 
claim that it originated in Yemen before spreading to Ethiopia and neighboring countries. 
However, according to data collected by British explorers, the Ethiopian origin seems most 
likely [49-50]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Khat (Catha edulis) plant 
 
Abu Rayhan Al-Biurni, a Persian scientist, carried out the first description of this plant 
during the 11th century. The oldest scientific report about this specimen dates back to the 18th 
century, when the botanist Peter Forskal identified the plant in Yemen, naming it Catha edulis 
[51-53]. 
The consumption of plants, and especially of khat, to take advantage of its stimulant 
properties is not a new practice. According to a famous legend, the first human that experienced 
khat was a Yemeni herder. He observed the effects that leaves caused in his goats, deciding to 
experience these same effects. To this end, the herder chewed the leaves, which is currently the 
exclusive method for the consumption of khat [54]. Chewing leaves to take pleasure of its 
stimulant effects become a deeply entrenched social and cultural tradition, practiced by the 
inhabitants of these geographical areas (Figure 6A), where there are no laws restricting its 
cultivation and consumption. It is estimated that about 5 to 10 million people do so daily [53]. 
This habit involves picking tender leaves of khat, beginning to masticate thoroughly one at time 
while users engage in discussions and social interactions. During the sessions, the leaves are 
chewed slowly over several hours and the juice is swallowed while the residue is putted into 
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one side of the mouth [48]. 
During the last two decades, this practice has gained global prominence as a result of 
migration, although khat use in western countries such as the United Kingdom, Canada and 
United States has recently become restricted and is now classified as a controlled substance of 
abuse [48]. Khat has won a recognized economic value comparable to other crops such as tea, 
coffee and cocoa [53]. 
 
 
 
Figure 6 – (A) Khat chewing; (B) Fresh khat leaves, ready for sale and chewing 
 
 
Traditionally, khat is used as a socializing drug although it is also sought by farm 
workers to reduce physical fatigue and by drivers and students for improving attention [54-55]. 
 
 
2.2 Active constituents of Khat 
 
The alkaloids present in khat have been investigated for years, but it was only in 1930 
that norpseudoephedrine or cathine [S, S (+) phenylpropanolamine] was identified in the 
leaves. Initially the stimulating power of khat was explained by the presence of this substance, 
until it was shown that its concentration in the leaves and respective potency were too low to 
justify the effects caused [49, 56]. 
 Subsequently, other studies have indicated the presence of another alkaloid in the plant, 
with a more potent stimulant power – cathinone [S (-) alpha - aminopropiophenone], a beta-
keto amphetamine analog (Figure 7), known as "natural amphetamine", since the effects are 
similar to those produced by other known psychostimulants as amphetamines and their 
congeners. This substance was found at high concentrations particularly in young leaves [49, 56-
57]. 
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Figure 7 – Chemical structure of amphetamine, cathine and cathinone 
 
 
Other researchers found that cathinone is a precursor that in khat leaves is 
enzymatically converted into cathine and norephedrine, the latter to a lesser extent. This 
transformation is fast in the adult leaves and slow in younger leaves. This can be explained 
presumably because in younger leaves the enzymatic development is still incomplete [49-50]. 
Thus, users of khat will choose, preferentially, to consume young leaves, where the amount of 
cathinone is high, thus obtaining the desired stimulating effects with less adverse systemic 
effects. 
Cathinone degradation by sunlight or heat was also checked, and to delay the process, 
the leaves of khat when harvested for sale are usually wrapped in banana leaves (Figure 6B) to 
retain the moisture and preserve freshness [58]. 
Many other chemical components were identified in khat plant including tannins, 
flavonoids, sterols, carotenes, terpenoids, essential oils, amino acids, proteins, vitamins and 
minerals [50, 58-59]. 
 
 
2.3 Effects produced by Khat consumption 
 
2.3.1 Physical sequelae 
 
 Cathinone is structurally and functionally similar to amphetamine (Figure 7). It causes 
the release of catecholamines originating Central Nervous System (CNS) stimulation in low 
doses, associated with an alertness, euphoria and sense of well-being. Cathinone has also 
peripheral sympathomimetic effects, such as increased respiration, body temperature, blood 
pressure and heart rate. Some cases of anorexia, hyperactivity and loquacity have been reported 
after khat consumption. Another common effect is insomnia, a condition that users try to 
overcome with sedatives or alcohol in order to neutralize the stimulating effect caused by khat 
[52, 56-57]. 
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 The adverse physical effects in humans resulting from high doses and chronic 
consumption of khat have been well studied and can be briefly described according to the 
physiological systems involved (Table 2). 
 
 
 
 
   
2.3.2 Dependence, tolerance and withdrawal 
 
 According to some authors, the habit of chewing khat can cause a moderate, but 
permanent, psychological dependence. After continued use, mild withdrawal symptoms have 
been reported, including lethargy, mild depression, recurring nightmares and tremors [49]. In the 
literature there is little information regarding the dependency on khat and regular consumers 
do not report difficulties to stop consumption. However a cessation of its use results in 
significant improvement of sleep and appetite [56, 62].  
Table 2: Adverse physical effects of khat [51-53, 59-61] 
Central nervous system 
 
Dizziness, impaired concentration, memory deficit, insomnia, headaches, 
migraines, conjunctival congestion, impaired motor coordination, tremors, 
stereotyped behaviors 
Respiratory system Bronchitis, tachypnea, dyspnea, tuberculosis 
Tachycardia, arrhythmias, palpitations, hypertension, vasoconstriction, 
ischemia, myocardial infarction, chest pain, pulmonary edema, cerebral 
hemorrhage 
Cardiovascular system 
Gastrointestinal 
system 
Dry mouth, polydipsia, tooth decay, brownish teeth, oral cancer, periodontal 
disease, oral keratotic lesions, chronic gastritis, gastric ulcers, esophagitis, 
constipation, hemorrhoids, paralytic ileus, duodenal ulcer, anorexia, weight 
loss, increased risk of upper gastrointestinal malignancy 
Hepatobiliary system Cirrhosis 
Genitourinary 
system 
Spermatorrhea, change in libido, impotence, urinary retention, renal toxicity, 
abnormal sperm 
Obstetric effects Low birth weight, stillbirth, impaired lactation 
Metabolic and 
endocrine effects 
Hyperthermia, sweating, hyperglycaemia 
Ocular effects Mydriasis, blurred vision 
Psychiatric effects Lethargy, irritability, depression and psychotic reactions 
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 Tolerance is difficult to assess since the tradition defines a maximum amount (100-200 
g) of khat to be consumed daily [50]. However, a certain degree of tolerance seems to be 
associated with an increase in blood pressure, heart rate, respiratory rate and body 
temperature [63]. 
 
 
2.3.3 Treatment of intoxications  
 
 Few reports on this topic have been enumerated. Giannini and collaborators (1992) 
reported two cases of addiction to khat treated with bromocriptine, following the same protocol 
as developed for the treatment of cocaine addiction [62]. 
 
 
2.3.4 Socio-economic effects 
 
Apart the negative health impact in the communities where khat is consumed regularly, 
impact on socio-economic conditions have also been reported. While the consumption of khat 
can be indirectly associated with absenteeism and unemployment due to the hours dedicated to 
daily ritual, on the other hand there are those who defend that a moderate intake of khat 
improves performance due to its stimulant effects, decreasing fatigue. Therefore, the work is 
extended over hours, due to an increase in the motivation of employees, thereby increasing the 
productivity and the economy. Another problem arises to the fact that these people spend a 
large part of the salary to feed the addiction to khat consumption, which leads the idea of 
possible dependency. Against this background, consumers seek incessantly income to pay for 
khat and may resort to inappropriate behavior such as criminal behavior and prostitution. 
However, apart to the losses associated, economic benefits for these producer countries can also 
be found in the sale and export of khat [57]. 
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3.1 History 
 
 Prior the confirmation of the cathine as one of the active ingredients of khat, synthesis 
procedures were carried out, discovering the first two synthetic cathinones: methcathinone 
(1928) and mephedrone (1929) [64]. The evident structural relationship of these substances 
with the amphetamine has led to a strong interest in these compounds, initially for therapeutic 
purposes. In the 1930s the methcathinone (also known as ephedrone) has been developed as an 
antidepressant in the Soviet Union, but was never marketed for this purpose due to its strong 
addictive potential [20]; the amfepramone (or diethylcathinone) was marketed as an appetite 
suppressant in the late 1950s [65]; from 1970 the pyrovalerone was used for a few years in the 
treatment of chronic fatigue and lethargy, which was also abandoned due to dependency issues 
[66]; bupropion was introduced on the market in 1985 as an antidepressant and later used in 
pharmacotherapy of smoking cessation, being the only cathinone derivative currently used for 
therapeutic purposes in the United States and Europe [67-68]. 
 For several decades methcathinone was consumed as a recreational drug without any 
kind of control, confirming its widespread abuse in the former Soviet Union, Russia and 
Western Europe, sprawling to the USA in the 1990s [20]. In 1994, the U.S. Government 
recommended the inclusion of methcathinone as a Schedule I controlled substance in the UN 
Convention on Psychotropic Substances [64]. However, a growing number of new derivatives of 
cathinones have emerged and its therapeutic potential has continued to be evaluated. In 1996, 
methylone was patented as antiparkinsonian agent and its similarity to amphetamine, 
particularly with MDMA was described [69].  
Over the next decade, the scenario of cathinone derivatives began to change, appearing 
now as "legal highs" in some countries. It was the case of methylone, which in 2004 emerged in 
the Japanese and European market under the name of "Explosion", being one of the first 
products to be sold in “smartshops” and on the Internet [70]. In turn, mephedrone appeared in 
Israel in the early 2000s, locally nicknamed "Hagigat", though its consumption was banned in 
2008 by the Israeli Government due to the large number of hospitalizations associated with 
their use [71]. However, other countries have shown interest in this product, starting to be 
marketed in Europe since 2007 [38]. Growing concerns about the safety of mephedrone and 
related derivatives have led to a series of restrictions in countries in which it was 
predominantly consumed, as it was the case of the United Kingdom that in 2010 has introduced 
these derivatives on a collective group of class B substances, under the Misuse of Drugs Act 
1971, having a specific legislation to deal with such substances [38].  
After mephedrone, other derivatives appeared on the market, such as flephedrone (4-
fluoromethcathinone) and two structural isomers (2 - and 3 - fluoromethcathinone) [43], as well 
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as naphyrone (also known as naphthylpyrovalerone or NRG-1) and MDAI (5,6-Methylenedioxy-
2-aminoindane) [8, 71]. 
In Portugal, mephedrone only became an illegal substance at the beginning of 2012 [72]. 
However, a growing number of fatal cases related to "legal highs", in particular with cathinone 
derivatives, led the new legislation to amend the law which now prohibit any activity related to 
the production, import, export, advertising, distribution and sale of new psychoactive 
substances, initially in the Madeira Archipelago, extended this year to the entire country [73-74]. 
The major events in the history of cathinone derivatives are summarized in figure 8. 
 
 
 
Figure 8 – Timeline associated with cathinone derivatives
   1928  Synthesis of methcathinone 
   1929  Synthesis of mephedrone 
   1930  Methcathinone marketed as an antidepressant in the Sovietic Union 
 
   1950  Amfepramone introduced as an appetite suppressant 
 
   1970  Abuse of methcathinone in Sovietic Union; treatments with pyrovalerone 
 
   1985  Bupropion introduced as an antidepressant 
 
   1991  Methcathinone abuse appears in USA 
 
   1994  Methcathinone scheduled 
 
   1996  Methylone patented as an antiparkinsonian agent 
 
   2004  Methylone emerged for sale in drug market 
 
   2007   Appearance of mephedrone in drug market 
 
   2008  Appearance of flephedrone and naphyrone (NRG) 
 
   2010  Legal restrictions enforced on cathinone derivatives in several countries 
 
   2012  (March) Banning of mephedrone in Portugal 
 
   2012  (October) Ban the production and sale of derivatives cathinones in Madeira 
 
   2013  (March) Ban the derivatives cathinones products in Portugal 
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3.2 Chemistry 
 
 The synthetic cathinones were developed taking into account the active ingredient 
found in the khat plant, cathinone. Its chemical structure can be considered as a prototype, from 
which were developed a lot of derivatives. This idea is due to the fact that all cathinones have in 
common the same chemical structure, comprising a benzene ring and a aminoalkyl side chain 
[64]. 
However, despite the similar central structure, derivatives can be chemically organized 
into four groups (Figure 9) [6]:  
 
A. “Classic” cathinones – consisting of a benzene ring substituted or unsubstituted and 
a straight side chain. Examples of these cathinones are mephedrone (4-MMC) or 
buphedrone. 
 
B. Pyrrolidinopropiophenone derivatives – consisting of a benzene ring substituted or 
not and a pyrrolidinyl ring in a side chain. This is the case of substances like MPPP 
(Methyl-α-Pyrrolidinopropriophenone) or MPBP (Methyl-α-
Pyrrolidinobutiophenone). 
 
C. "3,4-methylenedioxy" cathinones – are composed of a 3,4-methylenedioxyphenyl 
ring and a straight side chain, for example methylone, butylone and pentylone which 
are substances that may be similar to MDMA and are advertised as "legal ecstasy". 
 
D. "Mixed" cathinones – contain a 3,4-methylenedioxyphenyl ring and a pyrrolidinyl 
side ring. It is the model of MDPV (3,4-methylenedioxypyrovalerone), MDPPP (3,4-
methylenedioxy-α-pyrrolidinopropiophenone) and MDPBP (3,4-methylenedioxy-α-
pyrrolidinobutiophenone). 
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Figure 9 – Chemical structures of some elements of the class of synthetic cathinones, divided into four major groups: (A) “Classic” cathinones; (B) Pyrrolidinopropiophenone 
derivatives; (C) "3,4-methylenedioxy" cathinones; and (D) "Mixed" cathinones 
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All these new substances may be considered as phenethylamines derivatives, which also 
include amphetamines, with the particularity of presenting a ß-keto group on the side chain [64]. 
Thus, it is common cathinone derivatives being considered amphetamine analogs. This is shown 
in Figure 10, where it turns out, for example, that from the structural point of view, the 
cathinone, methcathinone and methylone are analogs of amphetamine, methamphetamine and 
MDMA respectively, reflecting only the difference of ß-keto fraction [75]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – Structural relationship between some cathinone derivatives and their amphetamine analogs  
[adapted from 75] 
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These new substances, due to the ketone group that enhances its polarity, are usually 
more hydrophilic, decreasing its ability to cross the hematoencephalic barrier, being thus less 
potent than their phenethylamine analogues. Consequently, this leads to an increase in the 
dosage of drug consumed to induce the desired effects [1, 75-77]. 
However, the set of derivatives with a pyrrolidinyl ring in its structure is an exception to 
this rule. This group has a high lipophilicity as the nitrogen atom present in its chemical 
structure is linked to three carbon atoms (Figure 9), forming a tertiary amine group, which 
confers this property [1, 15]. 
 
 
3.3 Patterns of use 
   
 
3.3.1 Commercial appearance 
  
The synthetic cathinones are usually acquired as amorphous or crystalline powder, with 
white or brownish coloration that can occasionally be presented as capsules or tablets. Some 
users report that this type of synthetic drugs has a characteristic odor and flavor [1, 22, 38]. 
 
 
3.3.2 Routes of exposure 
 
 This kind of products can be used by multiple routes of exposure, with the nasal 
insufflation and oral ingestion being the most common. Yet, other means like the rectal 
insertion, inhalation, intramuscular and/or intravenous application or techniques such as 
"bombing"1 and "keying"2 can be used. Multiple pathways can be combined in a single session [2, 
76]. 
  
 
3.3.3 Dosage 
 
 According to reports, typical doses of mephedrone and methylone are variable 
depending on the route of exposure used. According to some authors, the dose is 100 to 200mg 
for oral ingestion, starting the effects to appear after 30-45 minutes, persisting for two to five 
                                                        
1 Bombing is done by wrapping the cathinone powder in cigarette paper and swallowing it. 
2 Keying is done by dipping a key in powder then insufflating.   
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hours, varying with the stomach content [2, 22, 38, 71]. The inhalation allows a faster onset (10-20 
minutes), but on the other hand has a lower duration of action (1-2 hours), since it requires 
lower doses (usually varies between 25 and 75 mg) [2, 71]. Some users opt for two ways 
simultaneously in order to achieve the rapid onset and long duration [71]. In the case of 
intravenous exposure, users refer to onset and duration of symptoms extremely rapid (10-15 
minutes and 30 minutes, respectively) [2]. The rapid onset of effects is also described for rectal 
exposure where smaller doses are required when compared to oral ingestion [71]. 
In the case of MDPV ingestion, lower doses (10-15 mg) and a more potent effect in a 
shorter period of time (15-30 minutes) are reported. There are reports of cases whose effects 
lasted until 7 hours [22]. 
Due to the unknown purity of "legal highs", as well as the exact composition, the dose is 
difficult to assess [2, 76]. It is impossible to determine a "safe" dosage since negative side effects 
can result for all dosage taken. In addition, equal dosages may lead to different results in 
different individuals [71]. 
 
 
3.4 Pharmacokinetics 
 
 The information on this topic is quite limited, being part of the knowledge acquired 
through user reports, surveys, clinical information or sometimes information available on 
websites [38]. 
 The absorption of this type of products and the subsequent onset of desired effect is 
dependent upon the route of exposure. The absorption is delayed in the presence of food in the 
stomach, so that the effects appear later when the drug is consumed after meals [38]. 
Studies in rats and humans have shown that the synthetic cathinones can be 
metabolized by multiple pathways, which vary according to their molecular structure [69, 78-80]. 
Studies involving cathinones that have the ß-keto group and methylenedioxy group (Figure 11), 
for example the case of methylone and butylone, show that the major urinary metabolites (4-
hydroxy-3-methoxymethcathinone (4'-OH-3'-MeO or HMMC) and 3-hydroxy-4-
methoxymethcathinone (3'-OH-4'-MeO)) are produced by demethylenation followed by O-
methylation of the hydroxy group on the benzene ring. The metabolite HMMC has been shown 
to be the most abundant in rats and humans so its analysis may become essential to prove the 
consumption of these substances. Another metabolic pathway, although minor is N-dealkylation 
to a primary amine. In these substances it may also occur the reduction of the keto group to the 
corresponding amino alcohol [69, 78-79, 81]. 
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Figure 11 – Main metabolic pathways of ß-keto derivatives with 3,4-methylenedioxy ring in rats and humans [adapted from 69]
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Regarding cathinones structurally similar to mephedrone, metabolic pathways differ 
slightly. Based on the identification of metabolites of mephedrone in the urine of rats and 
humans, the following metabolic pathways have been postulated (Figure 12): N-Dealkylation to 
the primary amine (metabolites nr. 2 and 3), reduction of the keto moiety to the respective 
alcohol (metabolites nr. 3 and 4) and oxidation of the tolyl moiety to the corresponding alcohol 
(metabolites 5 and 6) [80]. The metabolite represented by the number 4 has only been detected 
in human urine samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 – Proposed scheme for the metabolism of mephedrone in rats and humans [adapted from 80].  
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conducted [82]. Taking into account the urinary metabolites generated, it was concluded that the 
major metabolic pathways in humans (Figure 13) include demethylenation (metabolite 2, 4, 6 
and 7), methylation of the dihydroxy metabolites (metabolite 5, 8 and 9), hydroxylation of the 
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followed by dehydrogenation to the corresponding lactams (metabolite 3, 4 and 8) and finally 
degradation to primary amines (metabolite 7 and 10). A screening study involving the human 
hepatic CYPs has found that the CYP2C19, CYP2D6 and CYP1A2 isoenzymes are capable to 
catalyze the reaction (demethylenation) of formation the initial metabolite, the demethylenyl-
MDPV, in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 – Proposed scheme for the metabolism of MDPV in humans [adapted from 82]. 
 
 
The excretion occurs mainly by urinary track, where metabolites with a hydroxyl group 
are excreted in the form of glucuronide and/or sulfate conjugates and another portion is 
eliminated without modification [22, 79-81]. 
 
 
3.5 Mechanism of action 
 
 Neurotransmitters are contained whitin small storage vesicles in the neuronal cells, 
until it fuses with the cell membrane and expels biogenic amines (as noradrenaline (NA), 
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effect (Figure 14) [84]. Amphetamine and other related phenethylamines exert its stimulant 
effects through increasing concentration of biogenic amines in the synaptic cleft. This process 
arises as a result of two main mechanisms (Figure 14). One of the mechanisms implies that the 
drug inhibits the reuptake of monoamines by membrane-bound carriers due to competition of 
drugs to substrate binding sites in the carriers. The second mechanism, suggests that the drug 
causes the release of neurotransmitters from storage vesicles. The release may be mediated by 
intracellular pH changes or by inhibition of a monoaminic vesicular carrier, the VMAT2 [1-2, 85]. 
The vesicular pH is slightly acid when compared with the cytoplasmic pH. This difference 
creates a concentration gradient by preventing the neurotransmitters to be released into the 
cell cytoplasm. Drugs such as MDMA and other similar change the permeability and the 
physiology of intracellular vesicles and carriers. These drugs move to the cell body, merge into 
storage vesicles and cause a hydrogen ion buffer, increasing the vesicular pH with consequent 
premature release of neurotransmitters into the cytoplasm before the vesicle merge with the 
cell membrane [84]. 
Monoaminic carriers are protein structures integrated into the cell membrane, 
responsible for the reuptake of neurotransmitters existing in the cleft, moving them back into 
the cytoplasm. In turn, the VMAT2 carrier is instructed to move back into the vesicles to be used 
again. Such carriers, when inhibited will block the entry of biogenic amines in the vesicle, 
staying free inside the nerve ending and subsequently in the synaptic cleft [84].  
The stimulant drugs also partially inhibit the activity of the enzyme monoamine oxidase 
(MAO), which is responsible for the metabolism of monoamine neurotransmitters in excess [15, 
84]. A schematic representation is given in Figure 14, taking MDMA as an example. 
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Figure 14 – Mechanism of action of MDMA at the level of the serotonergic neurons. (1) MDMA promotes 
the release of 5-HT by exchange at the SERT carrier. (2) At higher concentrations, MDMA penetrates into 
synaptic vesicles and promotes 5-HT release contained therein. Increased 5-HT is also due to inhibition of 
the metabolic degradation of this neurotransmitter by MAO in the mitochondria (3), inhibition neuronal 
reuptake system of 5-HT by SERT (4) and stimulation of 5-HT release in the synaptic cleft (5). (6) This 5-
HT release will stimulate postsynaptic receptors. However 5-HT has mechanisms to avoid the excessive 
increase of its levels in the synaptic cleft by self-regulation of 5-HT release by presynaptic receptors (7), 
increased formation of metabolites and autoxidation products of 5-HT in the synaptic cleft (8). The 
MDMA also promotes the decrease of 5-HT reserves for causing the inhibition of biosynthesis of 5-HT by 
tryptophan hydroxylase (TH) (9) [adapted from 86]. 
  
 
Given that the information about the mechanism of action of these new synthetic drugs 
is limited, extrapolations are made taking into account the structural similarity with 
amphetamine derivatives, whereby identical mechanisms are expected. Scientific evidence 
supporting this hypothesis, indicate that cathinones, such as amphetamines, interact with the 
plasma membrane transporters of dopamine (i.e., DAT), noradrenaline (i.e., NAT) and serotonin 
(i.e., SERT). However, various studies in vitro have shown a mechanistic dichotomy between the 
most common synthetic cathinones, as well as a variable selectivity for carriers [4, 85, 87-88]. A 
study found that the methylone and the methcathinone showed a lower activity at VMAT2 level 
 
 
37 
as compared with MDMA and methamphetamine, respectively [85]. In vitro studies with rat brain 
synaptosomes revealed that the mephedrone and methylone block the uptake of DA, NA and 5-
HT but also act as stimulants in the release of these neurotransmitters. Table 3 summarizes the 
results obtained, which confirms that mephedrone, methylone and MDMA act as non-selective 
substrates, unlike amphetamine, which is selective for NAT and DAT. It was also found that 
mephedrone and methylone exhibit similar release potency in all transporters despite 
mephedrone is about twice as potent. In turn, substances such as cocaine and MDPV were 
inactive as releasers. MDPV showed a different pharmacological profile comparing to other 
cathinones, revealing a potent selective blocker for catecholamines carriers (DA and NA) [4, 88]. 
 
 
Table 3: Effects of synthetic cathinones and comparison test drugs on transporter-mediated 
inhibition of uptake and stimulation of release in rat brain synaptosomes [adapted from 4] 
 Mephedrone Methylone MDPV MDMA Amphetamine Cocaine 
DAT uptake 
IC50 (nM ± S.E.M.) 
762 ± 79 1232 ± 133 4.1 ± 0.5 1009 ± 39 93 ± 17 211 ± 19 
NAT uptake 
IC50 (nM ± S.E.M.) 
487 ± 66 1031 ± 162 26 ± 8 450 ± 30 67 ± 16 292 ± 34 
SERT uptake 
IC50 (nM ± S.E.M.) 
422 ± 26 1017 ± 59 3349 ± 305 125 ± 11 3418 ± 314 313 ± 17 
DAT uptake 
EC50 (nM ± S.E.M.) 
[Emax %] 
51 ± 5 
[102 ± 2] 
117 ± 12 
[96 ± 1] 
Inactive 
42 ± 2 
[100 ± 4] 
5.8 ± 0.4 
[102 ±1] 
Inactive 
NAT uptake 
EC50 (nM ± S.E.M.) 
[Emax %] 
58 ± 11 
[99 ± 4] 
140 ± 17 
[94 ± 2] 
Inactive 
53 ± 7 
[95 ± 2] 
6.6 ± 0.7 
[92 ± 1] 
Inactive 
SERT uptake 
EC50 (nM ± S.E.M.) 
[Emax %] 
122 ± 10 
[101 ± 1] 
234 ± 35 
[98 ± 2] 
Inactive 
39 ± 5 
[103 ± 4] 
698 ± 71 
[97 ± 2] 
Inactive 
 
 
Another in vitro study [87] with HEK 293 cells was conducted to determine the potency of 
different cathinone derivatives in inhibiting the transport of DA, NA and 5-HT, confirming 
previously published data and adding new evidence. It was verified that in addition to 
methylone and mephedrone, also ethylone, butylone and naphyrone act as nonselective 
inhibitors, but like MDMA also induce serotonin release. Moreover, cathinone, methcathinone 
and flephedrone, as well as amphetamine and methamphetamine, act preferentially as 
inhibitors of catecholamine uptake and induce the release of dopamine. Also pyrovalerone is a 
potent and selective inhibitor of dopamine and noradrenaline uptake, without producing the 
release of monoamines. 
Thus, synthetic cathinones with a high affinity to a specific carrier will inhibit its actions, 
resulting in a higher concentration of neurotransmitter in the synaptic cleft. In this way, a 
greater affinity to noradrenaline transporter will increase the sympathetic effects and cause 
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signs and symptoms similar to those caused by ingestion of cocaine, amphetamine and 
methamphetamine [71]. By another hand, a greater affinity for serotonin has been associated 
with delusions, hallucinations and paranoia [84]. Of note the predominant action of all cathinones 
on the dopamine transporter is probably associated with a considerable risk of addition [4, 84, 87-
88]. 
 
 
3.6 Toxicological effects 
 
There are not scientific studies in humans to determine the adverse effects of these new 
compounds. All information is based on descriptions reported by consumers and medical 
entities. However, the fact that the user believes that he consumed a specific substance does not 
invalidate that actually has consumed a different one and this fact makes it difficult to assess 
this type of information. Furthermore, in the case of mixture of compounds it is difficult to 
attribute the adverse effect to a certain substance. Thus, caution is required when analyzing this 
information [44]. 
The clinical effects described are consistent with a sympathomimetic toxicity, denoting a 
clinical history similar to cocaine, methamphetamine or ecstasy intoxication. The desired effects 
reported by consumers include increased energy, sociability, euphoria, increased alertness, 
talkativeness and increased libido [2, 71]. Some synthetic cathinones users also report adverse 
effects such as sweating, palpitations, nausea, vomiting, headaches, muscle pain, muscle spasms, 
dizziness and short-term memory problems [2, 76]. Consumers who used the nasal route of 
administration also reported aggressive behavior and psychosis [76]. However, specific effects of 
cathinones are sometimes difficult to assess since they are often consumed in combination with 
other substances such as alcohol, tobacco, MDMA, cannabis and cocaine [2, 26]. 
 
These new synthetic substances may affect multiple organ systems, as it happens with 
natural cathinones (Table 4). 
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Table 4:  Effects associated with the consumption of synthetic cathinones reported by consumers and medical entities [2, 5, 27, 38, 44, 71] 
Cardiovascular Palpitations, chest pain, hypertension, myocarditis, tachycardia, disseminated intravascular coagulation 
Ear – Nose – Throat (ENT) Dry mouth, nose bleeds, nasal irritation, tinnitus, tongue disorder 
Abdominal pain, loss of appetite, nausea, vomiting, liver failure, abnormal liver function tests Gastrointestinal 
Skeletal Muscle Arthralgia, changes in extremities (discoloration, numbness, tingling, cyanosis, muscle tension and cramps), 
increased creatinine kinase, peripheral vasoconstriction, rhabdomyolysis 
Neurologic Disorientation, altered mental status, collapse, confusion, bruxism, dizziness, headaches, memory loss,  
tremors, convulsions, drowsiness, dystonia, hyperreflexia, myoclonus, paresthesia 
Ophthalmologic Blurred vision, mydriasis, nystagmus, dilated pupils 
Respiratory Shortness of breath, tachypnea, respiratory distress 
Psychological Anger, irritability, aggressiveness, anxiety, visual and auditory hallucinations, depression, dysphoria,  
euphoria, fatigue, increased or decreased concentration, talkativeness, incoherent speech, panic,  
paranoia, perceptual distortions, agitation, delirium, psychosis, anhedonia, suicidal ideation, self-mutilation 
Genitourinary 
 Impaired renal function, acute renal failure Renal 
Anorgasmia, erectile dysfunction, increased libido 
Others Body odor, dehydration, sweating, fever, insomnia, nightmares, rash, hyponatremia, hyperthermia 
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3.6.1 Hyperthermia 
 
Hyperthermia is one of the characteristic effects in MDMA-induced toxicity event cases 
in which body temperature reaching 43°C has been related [89-91]. Such hyperthermic reactions 
may contribute to several complications, including rhabdomyolysis, disseminated intravascular 
coagulation (DIC) and acute renal failure [89-91]. 
Studies with experimental animals show that the effects of MDMA on thermoregulatory 
system are strongly conditioned by room temperature. In general, animals exposed to MDMA in 
low ambient temperatures (below 22°C) had hypothermia, while at high temperatures (above 
28°C) MDMA causes severe hyperthermia [92-93]. Since these types of psychostimulants are 
generally consumed in hot and crowded environments (usually "rave" parties), the ambient 
temperature is frequently high. This fact, together with the prolonged motor hyperactivity, as 
well as the state of dehydration may potentiate the hyperthermic effects in the human 
thermoregulatory system [92]. 
Hyperthermic effects, as well as its consequent effects, are also reported in cases of 
consumption of synthetic cathinones (see topic 3.6 Toxicological effects). However, studies in 
rats after subcutaneous administration of mephedrone shows that at low temperatures (below 
20°C) there is a decrease in body temperature, but in case of high ambient temperatures (in the 
order of 30°C) there were no changes in opposite to what has been established for MDMA 
exposure. In both environmental temperatures studied, it was verified an increase in locomotor 
activity, although it is more meaningful for higher temperatures. These results show that the 
mephedrone exhibits, in vivo, thermoregulatory properties distinct from those that are 
produced by "Ecstasy" [94]. Thus, it can be deduced that despite the structural similarity between 
the synthetic cathinones and MDMA, not all information relating to MDMA can be extrapolated 
to these new synthetic drugs. 
 
 
3.6.2 Adulterant toxic effects 
 
 One of the potential factors that contribute to adverse reactions caused by recreational 
drugs is the concomitant use of other substances that can be intentional or through 
consumption of adulterants existing in marketed products [95]. Adulterants are very commonly 
found in illicit drugs and may be present for various reasons. To increase the drug volume and 
consequently the profit, manufacturers deliberately add many substances pharmacologically 
inactive, as the case of sucrose. But there are also pharmacologically active adulterants that are 
added in order to enhance and/or mimic the effect of psychotropic substances. A well known 
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example of an adulterant with such characteristics is caffeine. Adulterants may also be present 
unintentionally as a result of technical production or storage of products, taking as an example 
the alkaloids, microorganisms or other biological agents [96]. 
In the case of "legal highs", as has been already explained, information concerning the 
composition of commercial products is not always explicit or corresponds to reality. However, 
compositional analyses carried out on a wide variety of "legal highs" sold all over the world 
have found the presence of several adulterants, including benzocaine, lidocaine, procaine, 
glaucine, nicotinamide, caffeine, among others [6, 8, 16, 31]. 
Certain analysis have shown that caffeine is part of the composition of a wide variety of 
"legal highs", being the substance most commonly found in these new drugs [6]. There has been 
found that some of them contain only caffeine as pharmacologically active compound or often 
associated with other compounds but still at significant percentages (sometimes greater than 
87%, corresponding approximately to the consumption of 13L of cola drink). Consequently, the 
recreational use of these new products can result in severe cases of toxicity [33]. In fact, previous 
studies have shown that caffeine (10 mg/kg) significantly increases the mortality of rats when 
coadministered with a high dose of MDMA (15mg/Kg), causing also a high and lasting 
hyperthermic response, showing that caffeine exacerbates the acute toxicity of MDMA [95]. It was 
also found that the coadministration of caffeine (10 mg/kg) with MDMA (10 mg/kg) induces a 
deep tachycardia that is not observed in the case of administration of the substances alone, 
suggesting the existence of interaction between them [97]. 
 Thus, while that for many people substances as caffeine is taken as a safe substance, its 
intake simultaneously with these new products leads to a synergy of the stimulant effects, also 
exacerbating the toxicity produced by them alone, representing a risk to the health of users of 
this kind of recreational drugs [95]. 
 
 
3.7 Treatment of intoxications 
 
  The treatment of intoxications in cases of exposure to synthetic cathinones is mainly 
supportive, and there is no specific antidote. The available information to guide the treatment is 
restricted, but given the similarities of effects with amphetamines it seems likely that 
therapeutic strategies are also similar. Sedation is frequent and the use of large doses of 
benzodiazepines is required to control the agitation, seizures, hypertension and tachycardia. In 
the case of persistent hypertension the administration of vasodilators such as sodium 
nitroprusside or nitroglycerin is recommended. The internal and/or external cooling to treat 
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hyperthermia should be considered. The treatment of MDMA-induced hyponatremia is done 
through the water restriction or by administering a hypertonic saline solution [1-2, 76].
Patients should be monitored at cardiac level and body temperature. It should also be 
performed the evaluation of biochemical markers of muscle damage, electrolytes, renal and 
hepatic function, cardiac enzymes, as well as screening tests for drugs. Monitoring of patients 
must remain until the resolution of symptoms and stabilization of vital signs [22, 98]. 
 
 
3.8 Reported intoxications 
 
 A growing number of fatal poisonings, especially among the younger population, has 
recently been attributed to consumption of these new synthetic substances. However, the vast 
majority of laboratory analyses reveal the presence of multiple drugs of abuse, which 
complicates the assessment of the causal agent of death. Furthermore, the detection of these 
new substances and its metabolites in biological samples ante and postmortem does not 
necessarily mean that its consumption was the cause of death [1, 38]. 
 The synthetic cathinones, according to medical literature, have been directly involved in 
a growing number of fatalities [4]. The first fatal case, whose cause was confirmed and attributed 
to simultaneous use of methylone and butylone, is recent. The victim, 24 years old, showed 
severe symptoms of sympathomimetic intoxication - hyperthermia, tachycardia, tachypnea, 
hypertension, diaphoresis, hyperreflexia, tremors and coma. Despite the efforts, the patient 
developed a multiple organ system failures and succumbed [18]. 
 Fatal cases with laboratory confirmation of MDPV exposure have also been reported. 
The clinical condition comprised hyperthermia, delirium, and DIC [99]. 
 
 
There are also serious cases of poisoning that can reverse [19]. This was the case of an 
individual (25 years) who was transported to the emergency service for displaying a severe 
agitation and altered mental status after the consumption of "bath salts." The patient was 
hypertensive, tachycardic and hyperthermic (41.3°C, rectally). The individual cooling was 
immediately provided as well as the supportive treatment. On the day of his admission 
toxicological analysis was performed in urine, having been detected MDPV at a concentration of 
140 ng/mL. Despite the quick and appropriate intervention, the patient developed hepatic and 
renal failure and rhabdomyolysis, but his condition was reversed after a long hospital stay. It is 
unknown if the organs failure was due to direct cell toxicity induced by MDPV.
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In these successful cases, some individuals get a full recovery, while others have to do a 
prolonged follow-up of its clinical condition, with descriptions of people who became 
dependent on hemodialysis [100]. 
 
 
3.9 Addiction and withdrawal 
 
Regular consumption of high doses of synthetic cathinones induces tolerance, 
dependence and withdrawal syndrome after abrupt interruption. Signs of withdrawal were 
reported by users of methcathinone, mephedrone and MDPV after abrupt cessation, notably 
including depression, anergy, anhedonia, anxiety, fatigue and sleep cycle disturbances [1]. Users 
report the development of tolerance to “bath salts” describing them as highly addictive [5]. 
 
 
3.10 Detection in human samples 
 
 Currently, there are no quick screening tests for synthetic cathinones, but techniques 
such chromatography coupled to mass spectrometry may be useful in the analysis of blood, 
urine and gastric content samples, either in ante or postmortem specimens, allowing the 
detection of these synthetic substances and its metabolites [2, 69, 79-81, 101-102]. There are also data 
in the scientific literature showing that hair samples are also valuable matrices, particularly for 
retrospective studies of synthetic cathinones consumption [2, 44, 103-105].  
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The synthetic cathinones are representatives of a popular group of "legal highs", and 
there are currently about 40 known cathinone derivatives [23-25]. Some studies have been 
conducted for some of these individual derivatives, in particular relating to mephedrone, 
methylone, and butylone; however, the publications of studies related with other derivatives 
are limited. In addition, there are no data in the scientific literature related to acute or chronic 
health effects in animal and/or humans caused by the consumption of these new psychoactive 
drugs. In this way, further chemical and toxicological studies are necessary. 
 
Since the actual content of the commercial products is unknown, the concerns about 
safety increase, so it is of great importance develop analytical procedures in order to reveal 
their real compositions. Thus, considering that market products are not chemically 
characterized, one of the main objectives of this work consists in the chemical characterization 
of commercial products, sold in three distinct “smartshops”, announcing these new "legal highs" 
as “plant feeders”. The aim is to reveal the new psychoactive substances that compose them, as 
well as potential adulterants that can also have harmful effects, using highly powerful 
methodologies, in particular the GC-MS and NMR analysis. 
 
 Due to the scarcity of cytotoxity studies relating to these new psychotropic substances, 
the second major objective of the work is to evaluate the hepatotoxic effects of two of the “legal 
high” products and cathinone derivatives sold as individual agent via Internet, using a HepaRG 
cell line and primary rat hepatocytes culture as in vitro models.  
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1. Material and Methods 
 
1.1 Reagents and Standards 
 
All the reagents used were of analytical grade. Methanol (MeOH), chloroform, ethyl 
acetate, acetonitrile, acetone and n-hexane were obtained from Fisher Chemicals (Loures, 
Portugal) and diethyl ether was obtained from Pronalab (Lisbon, Portugal). Caffeine and 
trifluoroacetic anhydride (TFAA), 4-hydroxy-3-metoxybenzylamine hydrochloride (IS) were 
acquired from Sigma-Aldrich (Saint Louis, Missouri). Deuterated methanol was obtained from 
Cambridge Isotope Laboratories, Inc..  
The reference compounds (methylone, pentedrone, 4-MEC and MDPV) were purchased 
from Sensearomatic website. All the standards were characterized by mass spectrometry and 
nuclear magnetic resonance.  Methylone, 4-MEC and MDPV were also submitted to external 
analysis (by Instrumental Analysis Service of C.A.C.T.I., University of Vigo) in order to determine 
its elemental composition and consequently the molecular weight, as well as its purity. 
 
 
1.2 “Legal highs” products 
 
Twenty seven “legal highs” products were analyzed: 8 samples were purchased in 
Euphoria Smartshop (Porto), 9 in Magic Mushroom Smartshop (Porto), 9 in Magic Mushroom 
Smartshop (Lisbon) and 1 was delivered to the laboratory for analysis. Of the 27 samples, 22 
were powders and 5 were tablets. 
All products were acquired prior to the approval of Decree 54/2013[73], prohibiting the 
marketing of these products. 
 
 
 
1.3 Qualitative Screening by GC-MS 
 
 
1.3.1 Solvent selection 
 
Powders and tablets were homogenized in a mortar. Homogenized samples were 
dissolved in different solvents (chloroform, methanol, ethyl acetate, acetonitrile, acetone, 
diethyl ether and n-hexane) at a concentration of 1 mg/mL. Two µL of each solution was 
injected directly in GC-MS. 
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1.3.2 Analysis of commercial products by direct injection and after derivatization 
 
 
1.3.2.1 Standards and samples preparation 
 
Methanolic solutions of the standards and samples were prepared at a concentration of 
1 mg/mL. Two µL were injected automatically in GC-MS. 
Analysis after derivatization was also performed. The derivatization procedure was 
executed as described by Silva et al. [106] with appropriate adaptations. Standards and samples 
methanolic extracts were prepared at a concentration of 5 µg/mL and 10 µg/mL, respectively 
and were evaporated to dryness under nitrogen flow. Fifty µL of ethyl acetate and 50 µL of 
TFAA were added to the dried residue. Incubation was preformed at 70°C for 30 minutes. After 
cooling to room temperature the solution was dried under nitrogen flow. The obtained residue 
was dissolved in 100 µL of ethyl acetate and 2 µL was injected on the GC-MS apparatus. A 
summary of the procedures is shown in figure 15. 
 
 
1.3.2.2 GC-MS conditions 
 
GC-MS analysis was performed with a Varian CP-3800 gas chromatograph (USA) 
equipped with a Varian Saturn 4000 Ion Trap mass selective detector (USA) and a Saturn GC-MS 
workstation software version 6.8. The GC was equipped with a VF-5MS (30 m x 0,25 mm x 0,25 
µm) capillary column (Varian). A CombiPAL automatic auto sampler (Varian) was used for all 
experiments. The carrier gas was helium C-60 (Gasin, Portugal), at a constant flow of 1 mL/min. 
Injections was performed in split mode, with a ratio of 1/40. The injector port was heated to 
250 °C. The initial column temperature of 80 °C was held for 1 min, followed by a temperature 
ramp of 20 °C/min to 250 °C held for 2 min and 10 °C/min to 300 °C held for 20 min. Mass 
spectrometric detection was performed using an “ion trap” analyzer. The ion trap detector was 
set as follows: transfer line, manifold and trap temperatures were 280, 50 and 180 °C, 
respectively. The emission current was 10 µA and the maximum ionization time was 2500 µsec. 
Ionization was maintained off during the first 4 minutes to avoid solvent overloading. Total 
separation run time was 36 minutes. All mass spectra were acquired in electron impact (EI) 
mode and the mass ranged from 40 to 600 m/z. The injection volume was 2 µL and the analysis 
was performed in Full Scan mode. 
 
For the derivatized compounds analysis, the GC-MS conditions were properly adapted. 
Injections were performed in splitless mode. The injector port was heated to 250 °C, the oven 
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temperature was adjusted of 100 °C held for 1 min, followed by a temperature ramp of 15 
°C/min to 300 °C held for 10 min. The ion trap detector was set as follows: transfer line, 
manifold and trap temperatures were 280, 50 and 180 °C, respectively. The emission current 
was 30 µA and the maximum ionization time was 2500 µsec. Ionization was maintained off 
during the first 4 min to avoid solvent overloading. Total separation run time was 20 minutes. 
All mass spectra were acquired in electron impact (EI) mode and the mass ranged from 40 to 
600 m/z. The injection volume was 2 µL and the analysis was also performed in Full Scan mode. 
 
 
1.3.3 NMR analysis 
 
The samples (approximately 30 to 50 mg) were dissolved in 500 µL of deuterated 
methanol (methanol-d4). The nuclear magnetic resonance (NMR) spectra were recorded using a 
Bruker Avance 400 spectrometer with a frequency of 400 MHz for 1H and 104 MHz for 13C. The 
structures identification with the respective assignment of the proton and carbon signals was 
based on the analysis of NMR spectra obtained by 1D (1H, 13C, APT) and 2D (including the COSY, 
HMBC and HSQC experiments) techniques. The research was conduced by Dr. Helena Gaspar at 
the Faculty of Sciences, University of Lisbon, Portugal. 
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Analysis of Derivatized Samples 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 – Summary of procedures involved in “legal highs” characterization by GC-MS 
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1.3.5 Identification process 
 
The identification of each analyte was done by comparison of retention time and mass 
spectra of the tested compounds with standards injected under the same chromatographic 
conditions to ensure correct identification. 
The EI-GC-MS spectra of unidentified peaks were searched through spectra databases 
supported by NIST05 (National Institute of Standards and Technology) and SWGDRUG 
(Scientific Working Group for the Analysis of Seized Drugs). We also made our own mass 
spectra library. 
In order to confirm the identity of all compounds detected, derivatization with TFAA 
was applied. The trifluoroacylation reaction occurs in more electrophilic atoms: the nitrogen 
atom forming N-TFA and the oxygen atom forming O-TFA (Figure 16) [107]. 
 
 
 
 
 
 
 
 
 
Figure 16 – Generic derivatization mechanism with the TFAA reagent to obtain the O-TFA and N-TFA 
derivatives 
                    
 
 
NMR spectroscopy was also applied to confirm the structure of molecules identified by GC-
MS.  
Thus, all information was compiled in order to reveal the real composition of the products 
marketed as “plant feeders” obtained in the three “smartshops”. The process used for the 
products characterization is summarized in Figure 17. 
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Figure 17 – Schematic representation of the procedure used in the chemical characterization of “legal 
highs”, referring to the four crucial steps of the whole analysis 
 
 
 
1.4 Quantitative determination of cathinones by GC-MS 
 
 
1.4.1 Linearity studies 
 
Standards (methylone, pentedrone, 4-MEC and MDPV) and internal standard stock 
solutions were prepared at 1 mg/mL in methanol. All intermediate solutions were prepared 
daily by dilution of concentrated solution in methanol; working calibrators at 10, 50, 100, 500, 
1000, 2000, 5000 and 10000 ng/mL were prepared. One hundred µL of 4-hydroxy-3-
methoxybenzylamine hydrochloride (IS) at a concentration of 10 µg/mL were added to each 
solution. The derivatization process was performed and 2 µL were injected into the GC-MS. 
Regression curves were obtained plotting the peak-area ratio between each analyte and the 
internal standard against analyte concentrations, being the method linearity evaluated by the 
squared correlation coefficient (R2).  
 
 
1.4.2 Reproducibility studies 
 
Four “smartshops” products (3 powders, 1 tablet) were randomly selected to perform 
the semi-quantitative studies of cathinones. For each sample analyzed, three solutions were 
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prepared in methanol, daily, at a concentration of 1 mg/mL. For each initial solution, 
intermediate concentrations were prepared (5 µg/mL or 10 µg/mL) in triplicate. One hundred 
µL of 10 µg/mL IS was added to each solution and the derivatization process was carried out 
under the same conditions used in calibration curves.  
The reproducibility of the method was determined, being expressed through the 
calculation of the coefficient of variation for each final solution, in percentage [CV % = 
(SD/mean) x 100]. 
 
 
1.4.3 Estimation of the amount of interest compounds in “legal highs” samples 
 
Concentrations were calculated using the equation of the straight line (y = mx + b) of the 
respective analyte of interest and the mean was calculated for each of the independent 
solutions. The actual amount (mg) of the active ingredient in the four samples analyzed 
randomly (unknown quantities) was estimated. 
 
 
1.4.4 Statistical analysis 
 
Statistical analysis was performed using the GraphPad Prism 6 (version 6.0c) for Mac OS 
X. Multiple comparisons between more than two groups were performed by one or two-way 
ANOVA supplemented with Tukey’s test. Significance was accepted at P<0.05. 
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2.1 Chemical characterization of cathinone derivatives used as standards 
 
The cathinone derivatives used as standards (Methylone, 4-MEC, Pentedrone and 
MDPV) were acquired through a website (Sensearomatic.com) that is able to provide highly 
pure chemical products at a competitive price. Although the substances sold via this website (as 
well as in others) entitles as “research chemicals”, any person can acquire them, particularly for 
consumption. So the consumers of these new drugs can create, without any restriction, their 
own “designer mixtures”, becoming more economically appealing (Figure 18). 
 
 
Figure 18 – Template of one of the thousands of websites (Sensearomatic.com) from which any person 
can purchase several “legal highs”, for consumption or other purposes, without any restriction and at a 
very affordable price. To circumvent all the legal aspects, there is clear information that the products are 
“not for human consumption” and that do not have any responsibility if the products is illegal in the 
country to which the intended delivery. [Image taken from http://www.sensearomatics.net/4meccrystalline/, accessed 19/07/2013] 
 
To make sure that standards correspond to what is mentioned on the label, all were 
analyzed by GC-MS, whose mass spectra were compared with those already described in the 
literature (Figure 19) [40, 45-46, 108]. RMN analyses were also performed to determine the 
molecular structure of the compound. The results showed that all standards corresponded to 
the requested compound.  
The GC-MS and NMR analyses also show that pentedrone standard contained an 
isomeric impurity identified as isopentedrone (1-methylamino-1-phenylpentan-2-one), a by-
product of the pentedrone synthesis, in which the amino moiety and keto group change their 
place in the molecule [40]. Thus, this standard also served as confirmation of this minor 
compound. 
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Figure 19 – EI mass spectra of methylone, 4-MEC, pentedrone, isopentedrone and MDPV, respectively 
(direct injection) 
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 All cathinone derivative standards (with exception of pentedrone, which was only available 
in a small amount) were also subjected to elemental analysis in order to determine if they were 
hydrochlorides and also to determine their purity. The results of analyses carried out are 
described in Table 5. 
 
Table 5: Results of external analysis of cathinone derivatives standards 
Compound % N % C % H % Cl 
Theoretical 
molecular 
weight 
Experimental 
molecular 
weight 
Proposed 
molecular 
formula 
% 
Purity 
4-MEC 6.15 63.28 7.98 15.57 227.75 221.99 C12H17NO.HCl 97.47 
Methylone 5.75 54.21 4.97 14.55 243.71 238.77 C11H13NO3.HCl 97.97 
MDPV 4.50 61.62 7.13 11.37 311.84 304.40 C16H21NO3.HCl 97.61 
 
 
The results showed that the samples analyzed were actually hydrochlorides, showing all of 
them purity higher than 97%.  
All compositions were confirmed and purities obtained were high so that all standards have 
been considered for the analysis of chemical characterization of commercial products. 
 
 
2.2 Characterization of commercial products 
 
A total of 27 "legal highs" were purchased in three distinct “smartshops” (Euphoria in Porto 
and Magic Mushroom in Porto and Lisbon). A survey of all products sold as “plant feeders” or 
“bath salts” in these shops was conducted, being bought at least one sample of each. Some 
products were purchased on a large number of units, being a random choice in order to check 
the possible existence of qualitative and quantitative variability between supposedly identical 
products, as was previously described in the literature [6, 8-9, 16]. 
 
All products were packed in sealable silver foil bags or, occasionally, in transparent plastic 
bags. The packages featured the commercial name of the product, the alleged composition, the 
product quantity, and the dosage while “plant feeders”, along with the warnings “not for human 
consumption” (Figure 20). Some of the products presented its lot number but no other 
information was provided.  
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Figure 20 – Appearance of some commercial products 
 
 
The majority of powder products (86%) had a white color, however a small part had a 
yellowish color (Table 6), while the predominant color of the tablets was pink (Table 7). 
Variation was observed in the color of products with the same commercial name, acquired in 
the same “smartshop” (e.g. sample 1 and 2) or in different “smartshops” (e.g. sample 1 and 3; 6 
and 7; or 16, 17 and 18), which immediately raised the possibility of a different composition. 
 
The amount of products purchased ranged between 0.5 and 1 gram in the case of the 
powders. All tablet products had two units per pack. The weight of each tablet was 
approximately 500 mg. Considering the amount of 1 g for all products, the prices for the 
powders varied between 30 and 38 euros, while the price of tablets varied between 14 and 20 
euros (Table 6 e 7). This could be related to the product purity, leading us to consider the 
hypothesis that the powders are more potent than the products sold as tablets.  
 
Regarding the composition, the ingredient names printed on the packaging were recorded 
(Table 6 e 7) and the spelling mistakes were not corrected (e.g. phosphoates which should read 
phosphates). With the exception of samples 22, 26 and 27 all others have printed “ketones”, 
which can be interpreted as an indicator of the presence of cathinone derivatives. Samples 26 
and 27 (“Bloom+”) have described the presence of aminoalkyl benzofurans, which although not 
derived from cathinones, are structurally similar to amphetamine analogs. Most powder 
products also referred the presence of caffeine and glucose. In tablets, the printed composition 
was more elaborated once beyond the principle active other excipients related to the 
production of tablets were also present. The fact that some spelling errors have been detected 
and the composition described being extremely vague it seems that these products do not 
follow any kind of quality control. 
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Table 6: Main features of "legal highs" (powders) acquired for analysis 
 
 
Sample 
Number 
Product Name Smartshop Lot 
Product 
Color 
Chemical composition indicated on the label 
Price per gram 
(€/g) 
1 Bloom Magic Mushroom (Porto) N/A Yellowish Ketones, Vegetable extracts and Glucose 36 
2 Bloom Magic Mushroom (Porto) 2012 45X19P White 94% Ketones, 5% Caffeine and 1% Glucose 36 
3 Bloom Magic Mushroom (Lisbon) 2012 45X19P White 94% Ketones, 5% Caffeine and 1% Glucose 36 
4 Blast Euphoria (Porto) N/A White 89% Ketones, 10% Caffeine and 1% Glucose 36 
5 Blast Magic Mushroom (Lisbon) 2012 46X12P White 100% Ketones 36 
6 Rush Magic Mushroom (Porto) N/A Yellowish 89% Ketones, 10% Caffeine and 1% Glucose 30 
7 Rush Magic Mushroom (Lisbon) N/A White 89% Ketones, 10% Caffeine and 1% Glucose 30 
8 Invader  (Crabby) Euphoria (Porto) 2012 47X2P White 100% Ketones 37 
9 Invader (Cyclop) Euphoria (Porto) 2012 45X2P White 100% Ketones 37 
10 Bliss Magic Mushroom (Porto) 2013 X0619P White 95% Ketones, 5% Caffeine and 1% Glucose 30 
11 Bliss Euphoria (Porto) 2012 37014P White 100% Ketones 30 
12 Bliss Magic Mushroom (Lisbon) 2012 42X16P White 100% Ketones 30 
13 Charlie Magic Mushroom (Porto) 2012 40X17P White 100% Ketones 37 
14 Charlie Magic Mushroom (Porto) 2012 35017P White 100% Ketones 37 
15 Charlie Magic Mushroom (Lisbon) 2012 35017P White 100% Ketones 37 
16 Blow Magic Mushroom (Porto) N/A Yellowish Ketones, Vegetable extracts and Glucose 38 
17 Blow Euphoria (Porto) N/A White 94% Ketones, 5% Caffeine and 1% Glucose 38 
18 Blow Magic Mushroom (Lisbon) N/A White 94% Ketones, 5% Caffeine and 1% Glucose 38 
19 Kick Magic Mushroom (Porto) N/A White Ketones, Vegetable extracts and Glucose 30 
20 Kick Euphoria (Porto) 2012 36015P White 94% Ketones, 5% Caffeine and 1% Glucose 30 
21 Kick Magic Mushroom (Lisbon) 2012 38015P White 94% Ketones, 5% Caffeine and 1% Glucose 30 
22 MMB N/A N/A White N/A N/A 
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Table 7: Main features of "legal highs" (tablets) acquired for analysis 
 
Sample 
Number 
Product Name Smartshop Lot 
Product 
Color 
Chemical composition indicated on the 
label 
Price per two 
tablets 
(€/2 tablets) 
23 M 
Magic Mushroom 
(Porto) 
N/A Pink 
Ketones, Dicalcium, Phosphoates, 
Magnesium, Stearate 
16 
       
24 M 
Magic Mushroom 
(Lisbon) 
N/A Pink 
Ketones, Dicalcium, Phosphoates, 
Magnesium, Stearate 
16 
       
25 Bliss Euphoria (Porto) N/A Pink 
160 mg Ketones, 120 mg Lactose, 100 mg 
Corn starch, 50 mg Calcium stearate, 20 mg 
Magnesium stearate, 20 mg E124, 6 mg 
E132, 4 mg E142 
14 
       
26 Bloom + Euphoria (Porto) N/A Pink 
100 mg Aminoalkyl benzofurans, 120 mg 
Lactose, 100 mg Corn starch, 50 mg Calcium 
stearate, 20 mg Magnesium stearate, 20 mg 
E128, 5 mg E142 
20 
       
27 Bloom + 
Magic Mushroom 
(Lisbon) 
N/A Pink 
100 mg Aminoalkyl benzofurans, 120 mg 
Lactose, 100 mg Corn starch, 50 mg Calcium 
stearate, 20 mg Magnesium stearate, 20 mg 
E128, 5 mg E142 
20 
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2.3 Screening of psychoactive substances in “legal high” products 
 
 
Since the products labeled as “plant feeders” or “bath salts” are supposed to contain ketones 
(hypothetically cathinone derivatives), we started this work by studying the chemical profiling 
of different commercial products. Due to difficulties in accessing spectra libraries containing the 
mass spectra of these new substances, we had to create our own database taking into account 
the information collected, which contains the molecular structure, molecular weight, mass 
spectrum profile including base peak and other characteristic fragmentation ions (m/z) of the 
different compounds.  
Gas chromatography coupled to mass spectrometry technique was chosen to separate and 
identify the various compounds present in the "legal highs" samples. 
Initially, the extraction of compounds was tested with different solvents, being the methanol 
the solvent chosen for all analyzes. This choice is due to the fact that the cathinone derivatives 
are very polar molecules due to the presence of the ketone group and thus can be easily 
extracted by polar solvents such as methanol. 
Methanolic extracts of all samples were directly analyzed by GC-MS, resulting in different 
chromatographic profiles. All peaks were taken into account for the products characterization. 
Using the mass spectrum information of each chromatographic peak (e.g. base peak, molecular 
ion) we were able to establish relationships with the spectra database. By performing the 
intersection of information obtained from mass spectra interpretation with mass spectra 
database (NIST05 and SWGDRUG), and later with NMR data, we were able to identify 
cathinones in each commercial product. 
 
 
We were able to identify methylone, 4-MEC, isopentedrone, pentedrone and MDPV in 
commercial products by comparing retention times and mass spectra of each chromatographic 
peak with the respective standards. Positive matches were obtained for all compounds that 
initially had been identified through the database created. Thus, these six compounds were 
unequivocally identified. 
The other compounds were assigned potential identifications through the analysis of their 
mass spectra and comparison with compounds of our database. Due to the lack of standards to 
confirm or reject the other identifications, derivatization with TFAA was performed. Even the 
substances confirmed by standards were subjected to this process. Derivatization allowed us to 
obtain more clean chromatograms and get better separations with increased resolution and 
response (Figure 21).  
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Figure 21 – Full scan chromatographic profile of methanolic extracts (Sample 11 – “Bliss”) injected 
directly (red) into the GC-MS and injected after derivatization with TFAA (green), indicating the potential 
identification of compounds based on the analysis of mass spectra and new fragmentation patterns of 
molecules after derivatization with TFAA. The signal strength after derivatization is significantly higher, 
showing greater sensitivity of the method. 1 – Methedrone; 2 – Methedrone N-TFA 
 
 
Knowing the TFAA affinity for binding to the active hydrogen’s of amine and hydroxyl 
groups, it was possible to predict the chemical structures of the formed compounds whose 
identity was intended to determine. Knowing the molecular weight after derivatization and ions 
resulting from fragmentation, comparisons with the mass spectrum of the derivatized 
compounds (Figure 22) and derivatized standards were established in order to confirm the 
identification of compounds. 
 Of note, there are compounds without binding sites for TFAA, such as caffeine (Figure 22) 
and MDPV, whereby the molecular structure and consequently the mass spectrum are not 
altered after derivatization. 
Sample 11 – “Bliss” (Euphoria Porto) 
Direct injection of methanolic solution 
Sample 11 – “Bliss” (Euphoria Porto) 
Injection of derivatized solution 
 71 
A B 
C D 
 
 
 
 
 
Figure 22 – EI mass spectra corresponding to compounds of the sample 4 (“Blast”) 
A – Flephedrone EI mass spectrum (direct injection); B – EI mass spectrum of flephedrone N-TFA; C – 
Caffeine EI mass spectrum (direct Injection); D – Caffeine EI mass spectrum after derivatization 
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 Following the entire procedure, the chemical characterizations of all products purchased in 
different “smartshops” are summarized in Table 8.  In Table 9 are presented the retention time, 
base peak and other characteristic qualitative ions (m/z) for the compounds identified by GC-
MS before and after derivatization. 
 In a later stage of the experimental work, we had access to a new mass spectra database 
(SWGDRUG), which includes these new synthetic substances. Thus, all chromatographic peaks 
(direct injection) were also screened in this new library. It should also be noted that all products 
have been analyzed by NMR, thus confirming the molecular structure of each compound being 
an informative methodology in the distinction of positional isomers. These analyses allowed for 
example the distinction of 3-MEC and 4-MEC isomers.  
 
 
Table 8: Active ingredients detected in 27 “legal highs” acquired in three distinct “smartshops” 
after analysis by GC-MS and NMR. (*) “Legal high” sold in tablet form. 
Product name Smartshop Active substances identified by GC-MS and NMR 
Bloom 
Magic Mushroom Porto Isopentedrone, Pentedrone, 4-Methylethcathinone (4-MEC), Methylone, Dimethocaine 
Magic Mushroom Porto Ethcathinone, Pentedrone, Methedrone, Caffeine 
Magic Mushroom Lisbon Ethcathinone, Pentedrone, Methedrone, Caffeine 
Blast 
Euphoria Porto Flephedrone, Caffeine 
Magic Mushroom Lisbon Flephedrone, Caffeine 
Rush 
Magic Mushroom Porto Buphedrone, Caffeine 
Magic Mushroom Lisbon Isopentedrone, Pentedrone, Caffeine 
Crabby Euphoria Porto 3,4-Dimethylmethcathinone (3,4-DMMC) 
Cyclop Euphoria Porto 3,4-DMMC 
Bliss 
Magic Mushroom Porto Isopentedrone, Pentedrone, 3,4-DMMC, Methedrone, Caffeine 
Euphoria Porto Methedrone 
Magic Mushroom Lisbon Methedrone 
Charlie 
Magic Mushroom Porto Ethcathinone, Buphedrone, Caffeine 
Magic Mushroom Porto Ethcathinone, Buphedrone 
Magic Mushroom Lisbon Ethcathinone, Buphedrone 
Blow 
Magic Mushroom Porto 3-Methylmethcathinone (3-MEC), 4-MEC, Methylenedioxypyrovalerone (MDPV) 
Euphoria Porto 3-MEC, 4-MEC, Caffeine, MDPV 
Magic Mushroom Lisbon 3-MEC, 4-MEC, Caffeine, MDPV 
Kick 
Magic Mushroom Porto Isopentedrone, Pentedrone 
Euphoria Porto Buphedrone, Caffeine 
Magic Mushroom Lisbon Buphedrone, Caffeine 
MMB N/A Alpha-methyltryptamine (AMT), Dimethocaine 
M (*) 
Magic Mushroom Porto 4-Fluoroamphetamine 
Magic Mushroom Porto 4-Fluoroamphetamine 
Bliss (*) Euphoria Porto Methylone 
Bloom + (*) 
Euphoria Porto 
5-(2-Aminopropyl)benzofuran (5-APB), 6-(2-Aminopropyl)benzofuran (6-APB), 
5-(2-Aminopropyl)2,3-dihydrobenzofuran (5-APDB) 
Magic Mushroom Porto 6-APB, 5-APDB 
Table 9: Retention time (minutes), base peak (m/z) and other characteristic ions (m/z) of active 
ingredients detected directly by GC-MS and after derivatization with TFAA. Legend: A – available; 
N/A – not available; SW – SWGDRUG library; N – NIST05 library; m/z – mass to charge ratio 
 
 Without TFAA With TFAA 
Compound Standard Library 
Retention 
time 
(minutes) 
Base 
Peak 
(m/z) 
Characteristic 
ions (m/z) 
Retention 
time 
(minutes) 
Base 
Peak 
(m/z) 
Characteristic 
ions (m/z) 
Isopentedrone 
Pentedrone 
3-MEC 
4-MEC 
Methylone 
Ethcathinone 
Methedrone 
Flephedrone 
Buphedrone 
3,4-DMMC 
MDPV 
5-APB 
6-APB 
5-APDB 
4-Fluoroamphetamine 
AMT 
Dimethocaine 
Caffeine 
A 
A 
N/A 
A 
A 
N/A 
N/A 
N/A 
N/A 
N/A 
A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
A 
SW 
SW 
SW 
SW 
SW 
SW 
SW 
SW 
SW 
SW 
SW 
SW 
SW 
SW 
SW 
SW/N 
SW/N 
SW/N 
6,5 
6,7 
6,8 
6,9 
8,1 
6,1 
7,5 
5,7 
6,3 
7,3 
10,5 
6,6 
6,7 
7,2 
4,3 
8,4 
11,0 
8,8 
120 
86 
72 
72 
58 
72 
58 
58 
72 
58 
126 
44 
44 
44 
44 
131 
86 
194 
77, 91, 191 
77, 105, 191 
91, 119, 191 
91, 119, 191 
91, 121, 149, 207 
44, 77, 105, 177 
77, 107, 135, 193 
95, 123, 181 
77, 105, 177 
77, 105, 133, 191 
84, 121, 149, 275 
77, 131, 175 
77, 131, 175 
77, 134, 177 
83, 109, 153 
44, 77, 103, 174 
58, 120, 278 
55, 67, 82, 109 
N/A 
7,2 
7,5 
7,7 
9,0 
6,7 
8,3 
6,0 
6,9 
7,9 
11,3 
7,4 
7,6 
8,2 
5,0 
8,7 
11,8 
9,4 
N/A 
140 
119 
119 
149 
105 
135 
123 
105 
133 
126 
131 
131 
160 
136 
226 
86 
194 
N/A 
77, 105, 182, 287 
91, 168, 287 
91, 168, 287 
65, 110, 303 
110, 168, 273 
176, 182, 289 
110, 154, 277 
71, 77, 168, 273 
105, 174, 182, 287 
84, 121, 149, 275 
140, 158, 270 
140, 158, 270 
105, 133, 273 
89, 109, 248 
140, 154, 366 
65, 120, 374 
55, 67, 82, 109 
 
 
 
A total of 18 different substances were detected (Figure 23), belonging the vast majority to 
the class of synthetic cathinones. Substances of other classes were also found, namely 
dimethocaine (cocaine derivative), alpha-methyltryptamine (class of tryptamine), as well as 
other substances derived from phenethylamines class, namely the derivatives of benzofurans 
(5-APB, 6-APB and 5-APDB). 
In total we found 11 distinct cathinone derivatives (Figure 23), the pentedrone and 
buphedrone being the most frequent (9.1%) while flephedrone and methylone the less common 
(3%). However, despite the synthetic cathinones correspond to the representative class, the 
most common substance was caffeine (18.2%) (Figure 23), having the function of promoting the 
stimulant effects, being an adulterant. 
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Figure 23 - Different substances found in compositional analysis of the various "legal highs”. Yellow 
compounds are representatives of the synthetic cathinones class (66.7%), the orange are aminoalkyl 
benzofurans (7.6%), the red is a representative of amphetamine class (3%), while blue is of the 
tryptamine class (1.5%). The only cocaine derivative (3%) detected is highlighted in rose while caffeine 
(18.2%) is in beige. 
 
 
 
In the study of “legal highs” characterizations performed by Sobczak et al. (2012) [7], the 
synthetic cathinones were also the most frequent class of compounds (47%) followed by 
cannabinoids (45%), being the piperazines (7.5%) and phenethylamines (3.8%) the less 
numerous classes. The MDPV was the cathinone most frequently detected, although caffeine 
was the substance most commonly present. 
In turn the study conducted by Zuba et al. (2012) [6], on “legal highs” samples seized in 
“headshops” in Poland, showed that 449 products contained substances from different chemical 
classes, but active components can be classified into two major classes: cathinones and 
piperazines. In total, 61 substances were identified of which 14 belonged to the class of 
synthetic cathinones. The most common ingredients detected in “legal highs” seized were, in 
descending order: MDPV, caffeine, butylone, TFMPP, lidocaína, 4-MEC, mephedrone, pFPP, BZP 
and MDPBP. 
 
 
Pentedrone 
9,1% 
Buphedrone 
9,1% 
4-MEC 
7,6% 
Ethcathinone 
7,6% 
Methedrone 
7,6% 
Isopentedrone 
6,1% 
3,4-DMMC 
4,5% 
3-MEC 
4,5% 
MDPV 
4,5% 
Methylone 
3,0% 
Flephedrone 
3,0% 
6-APB 
3,0% 
5-APDB 
3,0% 
5-APB 
1,5% 
Dimethocaine 
3,0% 
Fluoroamphetamine 
3,0% 
AMT 
1,5% 
Caffeine 
18,2% 
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2.4 Inconsistency in the composition of the commercial products analyzed 
 
 
The number of compounds present in each “legal high” showed be variable. According to the 
results, there are products where only one active principle is present, under our conditions of 
analysis (for example sample 8, 9, 11, 12, 23, 24 and 25), but most “legal highs” are mixtures of 
psychoactive substances with a high number of constituents, as for example sample 1 (“Bloom”) 
or sample 10 (“Bliss”) that have five different components. Of 27 analyzed preparations, only 7 
(26%) contained a single component, 10 (37%) were composed of two psychoactive 
ingredients, 4 (15%) presented three substances, 4 products (15%) presented four ingredients 
and only 2 products (7%) had five different ingredients. 
It might be thought that the price of the products was related with the number of 
psychoactive compounds, however, according to our results it is not true since samples 8 and 9 
only present an active ingredient and have about the same retail price (37€) than for example 
the sample 1 which features 5 different compounds (36€).  
Zuba et al. (2012) [6] and Sobczak et al. (2012) [7] observed that it is more frequent the 
detection of a single active principle than a higher number. Sobczak et al. [7] have also found that 
it is more common to find samples with substances of the same class (66%), for example 
cathinones, than of different classes. Our results, in part, corroborate these findings since only a 
minority of products possesses a large number of substances. However, commercial products 
with two active principles are much more frequent (Table 8), in opposite to what has been 
reported by Zuba et al. (2012) and Sobczak et al. (2012). Our results are in agreement with 
those obtained by the same authors, being preferred the use of substances of the same class (e.g. 
the class of synthetic cathinones). The presence of mixtures of drug classes (e.g. synthetic 
cathinone class with cocaine derivatives) has a less expression, although in most cases the 
caffeine appear associated to the main class. 
 
Taking into account the GC-MS and NMR analyses, this study revealed a large diversity in 
the composition of the “legal highs” acquired. The 27 samples correspond to a total of 12 
different commercial products (“Bloom” (3); “Blast” (2); “Rush” (2); “Invader” (2); “Bliss” (3); 
“Charlie” (3); “Blow” (3); “Kick” (3); “MMB” (1); “M” (2); “Bliss” Tablet (1); “Bloom +” (2)). 
However, 19 different compositions were found, revealing the existence of a great 
compositional variability, which is an important finding from this study.  
 
Direct analysis of methanolic extracts by GC-MS showed different chromatographic profiles 
among different products and, in some cases, among products with the same commercial names 
(Figure 24). The high variability had been considered as different colors of the same products 
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were found. In all these cases (“Bloom”, “Rush” and “Blow”) analyses corroborate our suspicious 
of differences in the composition. Even in cases where sample colors were similar, clearly 
distinct compositions were found, particularly in samples of “Bliss” (10, 11 and 12), “Charlie” 
(13, 14 and 15) and “Kick” (19, 20 and 21). 
Apparently, a quantitative variability among products with the same composition was also 
detected (Figure 24 – Sample 2 and 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 – Full scan chromatographic profile of methanolic extracts (Sample 1, 2 and 3 – “Bloom”) 
injected directly into the GC-MS, indicating the potential identification of compounds based on mass 
spectrum analysis and revealing the qualitative and quantitative variability between products with the 
same commercial name. 1 – Isopentedrone; 2 – Pentedrone; 3 – 4-MEC; 4 – Methylone; 5 – Dimethocaine; 
6 – Ethcathinone; 7 – Methedrone; 8 – Caffeine 
 
Most cases of variability were observed in samples with the same name sold in different 
“smartshops”. However, in “Bloom” and “Charlie” products, acquired in the same “smartshops”, 
Sample 1 – “Bloom” (Magic Mushroom Porto) 
Sample 2 – “Bloom” (Magic Mushroom Porto) 
Sample 3 – “Bloom” (Magic Mushroom Lisbon) 
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composition was also different. All components differing in “Bloom” samples, while in “Charlie” 
one of the samples has caffeine as minority peak that is absent in the others. 
 
The analyses of two samples of “Rush” and three samples of “Kick” reveal distinct situations 
with extremely important evidences (Figure 25). The first corresponds to the fact that a 
commercial product with the same name (case of “Kick” and “Rush”), distributed by the same 
supplier (Aurafeel), sold in “smartshops” with the same name (Magic Mushroom) but situated in 
different locals (Lisbon and Porto), presents a completely different composition. We also found 
that the same product (“Kick”) sold in distinct “smartshops” (Magic Mushroom and Euphoria), 
in the same city (Porto), also has a different composition.  
The analysis also revealed that the same mixture could also be sold as products with 
different trade names (Figure 25), as checked in the sample 6 (“Rush” – Magic Mushroom 
Porto), samples 20 (“Kick” – Magic Mushroom Lisbon) and 21 (“Kick” – Euphoria Porto). In 
these three samples, chemical analyzes detected isopentedrone, pentedrone and caffeine. This 
suggests that the distributors (in this particular case all products were distributed by the same 
company – Aurafeel) do not know necessarily what they are selling, just being responsible for 
packaging and distribution, not being associated with sample processing. 
Finally, this analysis also allowed noting that products sold with the same name and same 
real composition (Sample 20 and 21 – “Kick”) feature a clear quantitative variability with regard 
to amount of caffeine (Figure 25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 – Analysis of “Rush” and “Kick” samples acquired in 3 different Portuguese “smartshops”: (A) 
Full scan chromatographic profile of methanolic solutions (1mg/mL) injected directly into the GC-MS, in 
parallel with the standard compounds. (B) 1H-NMR in MeOD (400.13 MHz) of the samples that allowed to 
assign the structure of the molecules present in the “plant feeders”.  
 
A 
B 
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The data presented by Zuba et al. (2012) [6] also indicate a high variability in the content of 
the products, being detected 10 different qualitative compositions in products named “Coco”.  
Some “Coco” products contained a single component, whereas others had mixtures. Even if the 
name was the same and packages were identical, the content was different. The real 
composition of “Coco Jumbo 0.5g” and “Cherry Coco Jumbo” was identical and the products 
contained six different active ingredients, whereas “Coco Jumbo 0.25g” contained only 
pentedrone. 
 
 
All variability found could be explained by the fact that the products belong to different lots 
as in the samples 13 and 14 (“Charlie”). However, there are different lots whose composition is 
the same as for example the case of samples 11 and 12 (“Bliss”) or 20 and 21 (“Kick”). 
Furthermore, in vast majority of cases we cannot draw conclusions about this topic once the lot 
number is not available, demonstrating once again the carelessness in the handling of these new 
products. 
In addition, in the same study developed by Zuba et al. [6], data show differences in 
qualitative and quantitative compositions even among samples packed together.  
 
 
In addition to the qualitative variability exploited above, in most cases it was also noted 
inconsistency between the “legal high” composition obtained by GC-MS analysis and what is 
label on the package. Caffeine was not detected in all products that appear described (e.g. 
sample 16). Other cases where the composition labeled was 100% ketones, chemically it was 
not observed (e.g. sample 5 it was found cathinones and caffeine). In relation to glucose, this 
was not detected in any of the samples analyzed. However we cannot conclude with certainty 
that this is not present in the products, because it may be at an insufficient amount to be 
detected or may be undetected under the conditions used in this study. This type of 
inconsistency has also been verified by other researchers [31], dedicated to the study of new 
psychoactive substances phenomenon. FTIR studies confirmed by GC-MS revealed that 6 out of 
7 samples acquired did not contain the labeled drugs but large amounts of caffeine. 
 
 
The lack of consistency in the qualitative composition is a serious problem. Significant 
variations in the contents of similarly labeled products containing psychoactive substances of 
variable potency and adverse effects is a serious threat for users and increases the risk of acute 
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harm and toxicity associated with their use. This inconsistency also hampers the assessment of 
the clinical state of the patient and consequently to provide appropriate treatment.  
When one substance is replaced by another or by a mixture, or the amount is higher than 
those labeled, the effects can be significantly different. These differences could have an impact 
on duration of action, the time required to cause the effects, and to the multiplicity of effects and 
respective interactions, etc, which could result in severe intoxications. Another matter of 
concern that should be the subject of further studies passes through the drug-drug interactions 
between the different components of the mixture and in cases of polydrugs these may worsen 
the clinical consequences. We can speculate that terrible consequences would come from taking 
these “legal highs”, but there are not enough evidences to state with certainty that the cause of 
intoxication and/or death is full responsibility of these new products. 
In addition, all these inconsistencies reported throughout the study demonstrate 
unequivocally the lack of control associated with these new substances regarded as “safe”, 
showing only sellers concern at the monetary impact level, putting aside the health of users. 
 
 
Despite all the problems associated with the new drugs phenomenon, it should be noted 
that none of the analyses detected compounds present in the list of prohibited substances [72, 74], 
in Portugal, at the time that these products were purchased. However, there are cases in the 
literature where substances have been identified in these so-called “legal highs” after their ban. 
Brandt et al. (2010) [8] obtained 24 products in 18 UK-websites over a period of 6 weeks 
following the ban of mephedrone and found that over 62% of analyzed products had this 
banned substance. Other study [31] revealed that five samples, also acquired through a UK-
website, had controlled substances (benzylpiperazine (BZP) and 1-[3-
(trifluoromethyl)phenyl]piperazine (TFMPP)) combined with caffeine. Due to the sudden ban 
on the sale of certain substances sellers continue selling prohibited products, rebranded as 
“new legal highs”, in order to reduce the stock. Taking into account this information, users of 
these “new products” are in possession of illegal substances assuming that they are legal and 
they are unaware of the consequent criminal and health risks. 
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2.5 Semi-quantitative analysis 
 
 
2.5.1 Semi-quantitative variability in commercial products 
 
 By comparing the chromatographic profile of a 10 µg/mL of a “legal high” (powder vs. 
tablet), it was found that the amount of cathinones in the tablet samples is lower (Figure 26). 
Comparing the majority peaks of each sample, it is verified that the signal of the tablet samples 
is about two to four times lower than the powder samples, when prepared in the same 
concentration and under the same conditions. This finding was observed in all “legal highs” 
purchased in the form of tablets although the signal strength varies slightly between them.  
 This finding associated with the fact that the tablets are sold at a significantly lower price 
(about half), gives emphasis to the hypothesis previously raised of the “legal highs” tablets 
being less powerful/pure in comparison to the powders. 
 
 
Figure 26 – Full scan chromatographic 
profile of derivatized solution (Sample 
14 – “Charlie” in the form of powder 
and Sample 23 – “M” in the form of 
tablet) injected after derivatization 
with TFAA. The powder signal strength 
is significantly higher, may be an 
indicator of higher purity of product. 
The potential identification is indicated 
based on the analysis of mass spectra 
and new fragmentation patterns of 
molecules. 1 – Ethcathinone N-TFA; 2 – 
Buphedrone N-TFA; 3 – 
Fluoroamphetamine N-TFA.  
 
  
 By comparing the chromatographic profile of samples whose real composition is identical, 
it was found in some cases an apparent quantitative variability (Figure 24 and 25). However, 
due to the lack of robust standards, it became impossible to perform a complete and reliable 
quantitative determination. 
 Still, there are studies in the literature [6] that reveal significant differences in the 
quantitative composition of the products with real qualitative content identical. The content of 
Sample 14 – “Charlie“ 
(Magic Mushroom Porto) 
Sample 23 – “M”  
(Magic Mushroom Porto) 
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MDPV detected in some preparations was about 10-15 mg per package and more than 100 mg 
in other packages. MDPV produces weak psychoactive effects for 3 to 5 mg and severe effects 
after administration of higher doses (higher than 20 mg), depending our route of exposure [5]. 
Thus, we can infer that administration of more than 100 mg of MDPV could be a health and even 
life-threatening. 
 
 
2.5.2 Linearity study 
 
 In our study, four samples were randomly selected in order to semi-quantify the substances 
that compose them. Three powders (Sample 1 – “Bloom”; Sample 16 – “Blow”; Sample 19 – 
“Kick”) and one tablet (Sample 25 – “Bliss”) were selected. In “Bloom”, it was quantified the 4-
MEC, pentedrone and methylone. In the sample 16 it was quantified 4-MEC and MDPV while in 
sample 19 only pentedrone. In turn, in the “Bliss” sample just methylone was analyzed, since it 
was the only component detected in qualitative analysis. 
 Regarding the quantification process, all samples and standards have been derivatized as it 
was concluded to be a more sensitive methodology. 
 Table 10 shows the calibration curves equations of standards tested for a given 
concentration range, as well as the squared correlation coefficient associated. Because the 
concentration found in the commercial products containing MDPV is lower than those 
containing other cathinones, we chose a range of lower concentrations (10-2000 ng/mL). All 
analytes showed high linearity for the concentrations range established, R2 values being higher 
than 0.99 (Table 10). 
 
 
Table 10: Calibration curves for 4-MEC, Pentedrone, Methylone and MDPV 
Compound 
Equation 
(y=mx+b) 
Range 
(ng/mL) 
R2 
4-MEC y=0.0002x+78,442 50 – 10000 0.99781 
Pentedrone y=0.0002x-83,787 50 – 10000 0.99909 
Methylone y=0.0002x+190,11 50 – 10000 0.99555 
MDPV y=0.0005x-3,7372 10 – 2000 0.99219 
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2.5.3 Intra-day precision of the method 
 
The precision of the method was determined (Table 11), and the results were satisfactory 
never exceeding values of 20% for intra-day determinations. 
 
Table 11: Intra-day precision of the method for the quantification of 4-MEC, Pentedrone, 
Methylone and MDPV in different “legal highs” products (n=3) 
Stock 
Solution 
Compound 
Bloom Blow Kick Bliss 
Mean 
(mg) 
SD 
CV 
(%) 
Mean 
(mg) 
SD 
CV 
(%) 
Mean 
(mg) 
SD 
CV 
(%) 
Mean 
(mg) 
SD 
CV 
(%) 
A 
4-MEC 296,9 53,4 10,1 623,1 51,0 8,2 -- -- -- -- -- -- 
Pentedrone 237,6 15,4 6,5 -- -- -- 705,3 31,2 4,4 -- -- -- 
Methylone 460,2 50,8 11,0 -- -- -- -- -- -- 133,3 7,9 5,9 
MDPV -- -- -- 13,4 1,3 9,4 -- -- -- -- -- -- 
B 
4-MEC 208,3 15,0 7,1 845,6 98,0 11,6 -- -- -- -- -- -- 
Pentedrone 146,1 1,7 1,2 -- -- -- 536,3 31,6 5,9 -- -- -- 
Methylone 385,0 33,3 8,6 -- -- -- -- -- -- 254,1 19,3 7,6 
MDPV -- -- -- 15,1 2,5 16,7 -- -- -- -- -- -- 
C 
4-MEC 219,0 21,7 9,9 746,9 77,5 10,4 -- -- -- -- -- -- 
Pentedrone 188,4 2,6 1,4 -- -- -- 579,0 40,5 7,0 -- -- -- 
Methylone 569,3 19,5 3,4 -- -- -- -- -- -- 215,4 9,8 4,6 
MDPV -- -- -- 25,7 3,5 13,6 -- -- -- -- -- -- 
 
 
  
 
2.5.4 Study of homogeneity of commercial products 
 
In order to verify the homogeneity of selected commercial samples (“Bloom”, “Blow”, “Kick” 
and “Bliss”) we took from the same sample three different aliquots (stock solution A, B and C).  
Figure 27 (A-D) results show the quantitative relation between the same component in the 
different solutions (for example 4-MEC of a “Bloom” solution A vs. 4-MEC of a “Bloom” solution 
B vs. 4-MEC of a “Bloom” solution C), as well as the relationship between the different solutions 
as a whole (e.g. solution A of “Bloom” vs. solution B of “Bloom” vs. solution C of “Bloom”). The 
results presented correspond to mean ± standard deviation (SD), for n=3. 
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Figure 27 – Semi-quantification of some substances (4-MEC, Pentedrone, Methylone and MDPV) present 
in “legal high” samples randomly selected and the quantitative relation between the same compound for 
different solutions. The figure A expresses the amount of 4-MEC, Pentedrone and Methylone (mg) in each 
gram of “Bloom” (1). Graph B expresses the amount of 4-MEC and MDPV (mg) in each gram of “Blow” 
(16), while the graph C expresses the amount of Pentedrone (mg) in each gram of “Kick” (19). Finally, the 
graph D expresses the amount of Methylone (mg) in each tablet of “Bliss” (25). The results are expressed 
through the mean ± SD, n=3 (* P<0.05; ** P<0.01; *** P<0.001; **** P<0.0001 for solution B or solution C 
vs. solution A). The groupings shown in figure A and B represent comparisons between the solutions as a 
whole. 
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Although the samples, visually, appear homogeneous and the same homogenization 
procedure was applied, it was verified that there are significant differences (P<0.05) (Figure 27) 
between the amounts of the compounds in the different solutions for the same product. This 
leads us to believe that the powders in the mixture of different “legal highs” can have different 
densities and/or granulometries, interfering in the reproducibility of the quantification values. 
This can be reflected in different amounts of substances presents in different portions of 
the products if the consumer does not use the entire product at once. This happens mainly in 
cases where the consumer is inexperient, being advised by the sellers to consume the product 
splitted. Thus, if there is a lack of product homogeneity, each time the user consume a portion, 
will consume different substances in unequal amounts at all times, so it is expected that the 
intensity of effects can vary, even within the same product. 
For a correct quantification of active principles and thus circumvent their heterogeneity, 
the ideal would be to perform a methanolic solution of the entire product and, subsequently, do 
all analysis from this global solution. 
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1. Material and Methods 
 
 
1.1 Chemicals and supplies 
 
 
All chemicals and reagents were of analytical grade. William’s E medium, insulin solution 
from bovine pancreas, hydrocortisone hemisuccinate, collagenase from Clostridium histolyticum 
type IA (≥ 600 CDU/mg solid), bovine serum albumin (fraction V), ethylene glycol-bis(ß-
aminoethyl)-N, N, N’, N’-tetraacetic acid (EGTA), sodium phosphate dibasic (Na2HPO4) 
gentamicin, dexamethasone, trypan blue solution, Triton X-100 and 3-[4,5-Dimethylthiazol]-2,5-
diphenyltetrazolium (MTT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibiotic 
mixture of penicillin/streptomycin, fetal bovine serum (FBS), trypsin 0.05%-EDTA and Hank’s 
buffered salt solution (HBSS) were obtained from Gibco by Life Technologies - Invitrogen 
(Barcelona, Spain). Sodium hydrogen carbonate (NaHCO3), potassium chloride (KCl), 
magnesium sulfate heptahydrate (MgSO4.7H2O), potassium dihydrogen phosphate (KH2PO4), 
calcium chloride dihydrate (CaCl2.2H2O) and dimethyl sulfoxide (DMSO) were purchased from 
Merck (Darmstadt, Germany). Finally, sodium chloride (NaCl) and 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) were obtained from VWR (Leuven, Belgium). HepaRG 
cell line was purchased from Gibco by Life Technologies - Invitrogen (France). 
MDMA (HCl salt) was extracted and purified from high purity MDMA tablets that were 
provided by the Portuguese Criminal Police Department. Methylone, Pentedrone, 4-MEC and 
MDPV were the same used in chemical characterization studies, acquired through a 
Sensearomatic website. “Bloom” and “Blow” samples used in this study were purchased from 
Magic Mushroom Smartshop (Porto, Portugal). All the products were fully characterized by 
NMR and MS methodologies (purity higher than 97%) and stored in a container with a desiccant 
substance at -20°C. 
 
 
 
1.2 Hepatocyte primary culture 
 
 
1.2.1 Animals 
 
Housing and experimental treatment of animals were in accordance with the Guide for the 
Care and Use of Laboratory Animals from the Institute for Laboratory Animal Research [109]. 
Adult male Wistar rats (Charles-River Laboratories, Barcelona, Spain), weighing 280 – 320 g 
were used in all experiments as a source of hepatocytes. Animals were acclimatized in 
polyethylene cages with wire-mesh at the top, lined with wood shavings, at an ambient 
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temperature of 20 ± 2 °C, humidity between 40 and 60% and 12h/12h light/dark cycle. The 
animals were kept in our animal facilities, having free access to standard rat chow and tap 
drinking water ad libitum.  
Surgical procedures for the isolation of hepatocytes were performed under isoflurane 
anesthesia and carried out between 10.00h a.m. and 12.00h a.m..  
 
 
1.2.2 Isolation of rat hepatocytes 
 
 
The technique used for the isolation of rat hepatocytes is based on a collagenase perfusion 
method described by Moldéus (1978) [110] also called “two-step perfusion”.  
Briefly, after anesthesia, a cannula was introduced in the hepatic portal vein (Figure 28) 
and the liver was initially perfused in situ with a modified Hank solution (NaCl 2.7 M, KCl 0.1 M, 
MgSO4.7H2O 16 mM, Na2HPO4 8.4 mM, KH2PO4 8.8 mM, NaHCO3 25 mM, HEPES 12.5 mM, EGTA 
0.6 mM and albumin 0.67%; pH 7.4), for 10 minutes at 37 °C, in order to remove the blood from 
the sinusoids and to decrease the extracellular calcium concentration, to consequently cleave 
the hepatic desmosomes (calcium dependent). In a second stage, hepatic collagen molecules, 
that ensure the mechanical stability of the liver, were hydrolyzed by ex situ perfusion with a 
Hank solution supplemented with collagenase and its co-factor calcium (NaCl 2.7 M, KCl 0.1 M, 
MgSO4.7H2O 16 mM, Na2HPO4 8.4 mM, KH2PO4 8.8 mM, NaHCO3 25 mM, HEPES 12.5 mM, 
collagenase 0.5 mg/mL and CaCl2 5.88%; pH 7.4). This last perfusion was carried out for 8 to 10 
minutes at 37 °C until the liver visibly loses its plasticity when lightly pressed. During both 
perfusions, the solutions were continuously aerated by a stream of carbogen (95% 02 and 5% 
C02) and the flow solution was maintained at 10 mL/min.  
Enzymatic dissociation was followed by a soft mechanical liver dissociation in Krebs-
Henseleit buffer (NaCl 0.42 M, KCl 16.9 mM, MgSO4.7H2O 4.2 mM, KH2PO4 4.2 mM, NaHCO3 25.5 
mM and CaCl2.2H2O 9.1 mM) supplemented with 12.5 mM HEPES and albumin (1%) (pH 7.4). 
The hepatocytes suspensions obtained have many non-parenchymal liver cells, including 
Kupffer cells, adipocytes, endothelial cells and non-viable parenchymal cells, being necessary to 
purify the suspension. Once the hepatocytes have a higher density than the non-parenchymal 
and dead cells, a suspension of highly enriched hepatocytes was obtained after low-speed 
centrifugations (300 rpm, 2 minutes) and washing with Krebs-Henseleit buffer supplemented 
with 12.5 mM HEPES (pH 7.4). 
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Figure 28 – Schematic representation of the hepatic portal vein cannulation and perfusion system 
 [Adapted from 86] 
 
 
1.2.3 Determination of cell viability using the technique of trypan blue exclusion 
 
Trypan blue is an organic dye with negative charge, which is excluded by the hepatocytes 
with cytoplasmic membranes intact, as a result of the maintenance of energy-dependent 
membrane potential. The loss of this potential due to cellular damage can cause membrane 
destruction, so trypan blue is included by the cells that rapidly begin to present a blue 
coloration, more evident in the nucleus; in turn, viable cells exhibit a spherical shape with well-
defined borders [111]. 
The trypan blue exclusion was the method chosen for determining the viability of the initial 
suspension cells, for being a quick method to first assessment of cell damage. However, like all 
methods, trypan blue exclusion also presents some disadvantages, in particular as regards the 
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subjectivity visual count of cells, the different counting techniques between different operators, 
the uneven distribution or even due to agglomeration of the cells. 
In our specific case, cell viability of the isolated rat hepatocytes, estimated through this 
technique, was always greater than 80%. 
 
 
  
1.2.4 Isolated rat hepatocyte culture 
 
 
A suspension of 5x105 viable cells/mL in complete culture medium (William’s E medium 
supplemented with 10% FBS, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 10 µg/ml 
gentamicin, 2ng/mL insulin and 5nM dexamethasone) was seeded in 96-well plates (BD 
Biosciences, Oxford, UK), in a density of 156250 viable cells/cm2. Cells were incubated at 37 °C 
with 5% CO2, overnight for cell adhesion. The day after, to the cells was added culture medium 
without FBS and incubation with test compounds was performed. 
 
 
 
1.3 HepaRG cell line routine 
 
 
HepaRG cells were cultured in growth medium composed of William’s E medium (with L-
glutamine), supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL 
streptomycin, 5 µg/mL bovine insulin and 50 µM hydrocortisone hemisuccinate. The cells grew 
in 75 cm2 canted-neck tissue culture flasks (Corning, NY, USA) under a humidified atmosphere 
of 5% CO2/95% O2, at 37 °C. The medium was renewed every 2 to 3 days. 
After reaching 80-90% of confluence, the cells were shifted to the same medium 
supplemented with 2% DMSO to stimulate differentiation. Differentiation medium was also 
changed every 2-3 days for two weeks. Finally, differentiated cells were gently detached by 
trypsinization, seeded into 96-well plates at a high density of 450000 viable cells/cm2 and 
incubated at 37 °C with 5% CO2 overnight for cell adhesion.  
 
 
 
1.4 Incubation of the primary rat hepatocytes and HepaRG cells with test compounds 
 
 
Stock solutions (50 mM) of MDMA (as reference compound), pentedrone, methylone, 4-MEC 
and MDPV salts were prepared in ultra-purified sterile water and were at least 10 times more 
concentrated than the highest concentration tested to prevent media dilution.  
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Stock solutions of “Bloom” and “Blow” were also prepared in ultra-purified sterile water, in 
such a way that the concentration of main active ingredient of the commercial product 
(methylone and 4-MEC, respectively) also matched the 50 mM.  
All stock solutions were stored at -20 °C and subsequent dilutions were freshly prepared in 
cell culture medium before each experiment. 
 
 
Primary rat hepatocytes and HepaRG cells were seeded onto the central 60 wells of 96-well 
plates, in densities defined above, in a volume of 200 µL of the corresponding complete culture 
medium. Peripheral wells on the plate were filled with HBSS to prevent evaporation and 
concentration of test solutions. After adhesion, the medium was gently aspirated and the cells 
were exposed to the test drugs dilutions prepared in fresh culture medium, in a humidified air 
atmosphere containing 5% CO2, at 37ºC, during a incubation period of 48 hours. The 
concentrations (0.05 – 5 mM) were selected to cover the whole effect range, from undetectable 
effects to maximum induced cell death. Each individual plate also included negative controls 
(i.e., no test agents) and positive controls of cell death (culture media with 1% Triton X-100). 
 
 
 
1.5 The MTT reduction viability assay 
 
 
The cytotoxic effects of MDMA and cathinone derivatives, individually and as products sold 
in “smartshops”, were determined using the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl 
tetrazolium bromide (MTT) reduction assay. The mitochondrial reductases of viable cells 
reduce the MTT dye to purple formazan crystals that can be spectrophotometrically quantified. 
Tetrazolium ring is cleaved in active mitochondria, and the reaction occurs only in living cells. 
Therefore, the assay results will reproduce mitochondrial function and, consequently, cell 
viability [112]. 
 
After incubation for 48 h, the medium was removed and 200 µL/well of cell culture 
medium containing 500 µg/mL MTT was added to the attached cells. Plates were incubated at 
37 °C, for 30 min (HepaRG cells) or 1h20 minutes (primary hepatocytes). Finally, the cell culture 
medium was aspirated and the formed intracellular formazan crystals were then dissolved in 
100 µL/well of 100% DMSO. 
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The spectrophotometric analysis was run at 550 and 690 nm in a 96-well plate reader 
(PowerWaveX; Bio-Tek, Winooski, VT, USA). Data were obtained from five independent 
experiments for primary hepatocytes and three independent experiments for HepaRG cells, 
with each test plate containing quadruplicates of increasing concentrations of the tested drugs.  
 
 
 
1.6 Regression modeling 
 
Curves of normalized mortality values (effect) versus log of concentration (mM) were 
constructed and analyzed using the best-fit approach [113]. In the present study, the logit 
function was employed: Y = θmin + (θmax – θmin)/(1+exp (-θ1-θ2*log (x))), where θmin and θmax are 
the minimal and maximal observed effects, respectively; x is the concentration of the test drug; 
θ1 is the parameter for the location and θ2 is the slope parameter. 
All of the nonlinear regression models describe sigmoidal concentration-response 
relationships and the plots were constructed using the GraphPad Prism 6 (version 6.0c) for Mac 
OS X. MTT data are presented as mean ± 95% confidence interval (CI). The EC50 values were 
determined for each individual drug and mixture, allowing for comparison between drugs. 
 
 
1.7 Calculation of predicted mixture effects 
 
After characterization of concentration-response curves of the individual agents, the effects 
of the “legal high” mixtures were predicted assuming additive joint responses. The expected 
effects were calculated using the concentration addition (CA) and independent action (IA) 
approaches, as described in Payne et al. [114] and used as a reference for the assessment of 
combination effects in terms of synergism (if the observed effects are greater than additive 
predictions), additivity (if the experimental mixture outcomes equal the prediction) and 
antagonism (if the experimental joint effects fall short of additivity) [115].  
Briefly, the concept of CA is based on the assumption that the mixture constituents have 
similar modes of action, which means that any component can be replaced partially or totally 
with another without changing the overall mixture effect [116]. This means that each individual 
component contributes to the global joint effect by acting in proportion to its concentration, 
even at concentrations producing no effect. The IA alternative approach better describes 
combination effects of drugs with dissimilar mechanisms of action with each agent interacting 
at differing sites of action [117]. In this case, the fractional response of one individual component 
is supposed to be independent from those induced by other components, presuming that 
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mixture components present at zero effect concentrations will not contribute to the overall 
effect. 
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Chapter 2 - Results and Discussion of 
the cytotoxicity studies 
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2.1 Features of primary hepatocytes and HepaRG cells 
 
In drug screening assays, the hepatotoxicity is one of the parameters of primary concern, 
since the liver is an organ responsible for biotransformation and elimination of toxic 
compounds from the human body, as well as being a primary target for allocation by 
xenobiotics [114]. The vast arsenal of vital biochemical functions performed by the liver requires 
an appropriate architecture, therefore the vast majority of all hepatic functions, including 
xenobiotic biotransformation, is performed by hepatocytes that constitute about 80% of the 
parenchymal liver cells. Hence, most of the hepatic in vitro models for toxicity studies are based 
on hepatocytes [115]. Taking this into accout, a wide range of liver-derived in vitro models have 
been developed and are now available for toxicological studies. Primary rodent hepatocyte 
cultures and hepatoma-derived cell lines are an important part of this in vitro models [116-120]. 
Primary cultures of rat hepatocytes (Figure 29 A) are a good alternative to human cells 
often used in toxicological studies because they present higher metabolic responses than the 
common human cell lines and the inter-donor variability can be minimized by selecting animals 
of the same sex, age and with similar feeding regimes [121]. Although primary hepatocytes are 
clinically relevant, cell lines are frequently used as alternatives. The hepatocyte cell lines 
present some advantages over freshly isolated hepatocytes, such as higher availability, 
unlimited life, stable karyotype and the fact that they are easy to handle and grow continuously 
[116, 118]. One disadvantage associated with hepatoma cells involves the limited extent of its 
biotransformative activity by some cytochrome P450 enzymes or by their low levels of when 
compared to a normal adult liver [118]. The HepaRG cell line has the ability to differentiate into 
hepatocyte-like cells and biliary-like cells, reaching maximum differentiation after 2 weeks of 
exposure to a 2% DMSO supplemented medium (Figure 29), expressing highly differentiated 
functions [117, 121-125]. For most metabolizing genes, the expression levels are associated with the 
presence of DMSO and the expression of CYP isoenzymes generally decreases when DMSO is 
removed from the medium, whereas carriers and the liver-specific factors remain unchanged 
[126]. Thus, it is suggested a dual effect of DMSO in cells, affecting not only their differentiation as 
well as gene expression in differentiated cells. Figure 29 shows HepaRG cells non-differentiated 
(B) and HepaRG cells after differentiation in culture medium containing 2% DMSO (C). 
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Figure 29 – (A) Microscopic appearance of freshly isolated rat hepatocytes in a total magnification of 
100x. Figures B1 and B2 shows microscopic appearance of HepaRG cells to 80-90% of confluence in a 
magnification of 100x and 200x, respectively. Figures C shows the HepaRG cells after 18 days of culture in 
the presence of differentiation medium with DMSO in a magnification of 100x (B1) and 200x (B2). H –
hepatocyte-like cells; BC – bili canaliculus. 
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2.2 Yield and viability of cell suspensions of isolated rat hepatocytes 
 
More important than the amount of isolated hepatocytes (yield), is their quality, i.e., the 
percentage of viable cells in suspension. After the isolation process, it is preferable to obtain a 
small number of cells but intact than getting a large quantity being the vast majority non-viable.  
Thus, after the rat liver perfusion, mechanical dispersion of cells must be performed carefully to 
minimize the loss of viability of the final suspension. 
The variability of cell viability was checked during the assays.  The cell suspensions used 
for the experiments showed viability between 81 and 90.2%. These values are within the ones 
reported by other authors whose work presented values between 80 to 97% also obtained with 
Wistar rats [127-128]. The number of cells obtained in each suspension ranged between 124 to 
245x106 cells per animal.  
For good results in terms of yield and viability, the experience factor during the perfusion 
technique implementation also seems determinant. An efficient and rapid cannulation of the 
portal vein, to ensure fast and uniform perfusion of all hepatic lobes, is very important in order 
to obtain favorable results. Parts of the liver that does not change color immediately when 
perfusion start, represent a poor cannulation, indicating further areas which have not been 
digested by collagenase. 
 
 
2.3 Test compounds 
 
As previously described, the number of intoxications and deaths associated with synthetic 
cathinones consumption increased considerably [4, 18-19, 99-100]. The inconsistency of effects and 
their magnitude is hard to explain. However, one possible explanation for this aspect implicates 
a pattern of polydrug abuse, often associated with the consumption of “legal highs”, as it was 
evident through the chemical characterization studies. 
The present study aimed to evaluate the cytotoxic effects of synthetic cathinones 
derivatives and real mixtures of this derivatives sold as “plant feeders”. Two “legal highs” were 
selected for cytotoxity study: “Bloom” and “Blow”. The first was chosen since its major 
component is the methylone, the direct analogue of “ecstasy”. In turn, the “Blow” was chosen as 
display in its composition 4-MEC that is structurally similar with one of the most popular 
synthetic cathinone (mephedrone) [108] and MDPV, which is one of the most potent derivatives 
due to the presence of a tertiary amine group in its molecular structure [1, 15].  
In order to accurately estimate the effects of a mixture, information about the individual 
responses of each of the constituents is required. Thus, all the major substances present in these 
products were studied alone in the same conditions as the mixtures. 
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One of the most popular drugs in the world [129] belonging to the amphetamine-class, 
MDMA, was also considered for the study, since it detains structural similarities with the 
synthetic cathinones, allowing a comparison of the hepatotoxic potency of the different drugs. 
For this purpose, stock solutions at a concentration of 50 mM for all products were 
prepared. Stock solutions of “Bloom” and “Blow” products were prepared in such a way that the 
concentration of major compound (methylone and 4-MEC, respectively) was fixed at 50 mM and 
the concentration of the remaining components of the mixture has been determined taking into 
account this main concentration. Thus, the peak area of the main active ingredient of the 
commercial product, obtained by gas chromatography, was equal to that obtained for the 
respective pure compound at desired concentration (50 mM) (Figure 30).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30 - Full scan chromatographic profile of “Bloom” stock solution with methylone at 50 mM and 
methylone standard also at 50 mM, injected directly into the GC-MS, showing equal areas and therefore 
equal concentrations. 
 
 
Taking into account this principle, the concentration of methylone, 4-MEC and pentedrone 
in the “Bloom” product used for cytotoxic study is 50, 33 and 31 mM, respectively. In turn, in the 
“Blow” sample, the concentration is 50 mM for 4-MEC and 1.8 mM for MDPV. 
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Therefore, the stock solutions were diluted maintaining the ratio between each mixture 
constituent unchanged. Serial dilutions covered a wide range of concentrations (0.05 – 5mM) 
for all test substances to describe the complete response range, from 0% cell death to maximum 
induced cell death, when using the MTT cytotoxicity assay. 
 
 
2.4 Concentration-response relationship of individual agents in primary cultured 
hepatocytes 
 
In the MTT assay, all tested single agents yielded reproducible effects in a concentration-
dependent fashion, resulting in increased cell death with the rising of chemical concentration 
(decreased percentage of cell viability). The shape of the concentration-response curves for the 
individual drugs tested were relatively similar, as well as their maximal effects, with the 
exception of pentedrone which presents values of cell death more pronounced to higher 
concentrations evidencing a higher slope compared to other substances. More significant 
differences were observed essentially in EC50 values as shown in figure 31. 
 
MDMA has an EC50 value of 0.754 mM. Methylone with an EC50 of 1.18 mM shares a 
similar potency with 4-MEC (EC50 1.29 mM), however with significantly higher values (P<0.05) 
than MDMA, being consequently drugs which individually offer lower cytotoxicity. In turn, there 
are no significant differences between MDPV (EC50 0.742 mM) and pentedrone (EC50 0.647 mM), 
being more cytotoxic than MDMA, although not significantly. 
Due to the presence of the pyrrolidinyl ring and the tertiary amine group, MDPV, as 
previously mentioned, is more lipophilic than other cathinones, showing greater facility to cross 
barriers [1, 15]. Thus, it was expected that MDPV was the most cytotoxic compound in the MTT 
assay. Although the EC50 values of pentedrone and MDPV were not significantly different, the 
first derivative appeared to be more cytotoxic at high concentrations, whereas for lower values, 
MDPV showed a higher cytotoxicity. Thus, through the MTT assay we can conclude that MDPV is 
actually one of the most powerful cathinones, showing its maximum hepatotoxicity at 
concentrations below 0.5 mM, as MDMA. 
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Figure 31 – Regression models for the cytotoxicity effects of individual cathinones, using isolated rat 
hepatocytes as a model at 37 °C. The grey line shows the EC50 and ECmax for each response curve and the 
dashed lines show the 95% confidence interval belt of the fit. Data were normalized to negative 
(untreated) and positive (1% Triton X-100) controls. Data were obtained from five independent 
experiments run in triplicate. 
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2.5 Significant synergic/additive mixture effects are observed in “legal highs” 
 
 
Assessments of mixture effects in terms of synergism, antagonism or additivity depend on 
the determination of the expected effect of a given mixture. After characterization the 
concentration-response curves for the individual cathinones in terms of shape, slope and 
maximal effects, the CA and IA models were applied for modeling the expected effects of “legal 
highs” mixtures. As showed in figure 32, the two additive models produced very similar 
expectations and confirm that both are suitable for predicting the mixture effects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32 – Predicted and observed effects of “Bloom” and “Blow” mixtures and their individual agents in 
MTT assay. Circles represent individual data points of the “Bloom” and “Blow” mixtures. The dashed lines 
show the prediction according to concentration addition (CA) and independent action (IA). The grey lines 
show the EC50 and ECmax for each response curves. Experimental data derive from five independent 
experiments run in triplicate.  
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By the analysis of “Bloom” mixture effect in figure 32, it is observed that the predicted 
curve according to the CA and IA models are shifted to higher concentrations values, assuming 
that the mixture has strongest effects than expected. This displacement curves is indicative of a 
synergism, since smaller concentrations than expected are necessary to produce the same 
effects. On the other hand, for “Blow” mixture the observed and experimental EC50 values are 
similar, revealing an additivity situation, although in lower concentrations the mixture curve is 
slightly shifted to the right, i.e. higher concentrations than expected are required to obtain the 
same effects; in higher concentrations mixture is slightly shifted to the left, i.e. smaller 
concentrations are needed than those provided by the mathematical models for the same 
effects. 
Despite these results, it is necessary to take into account that the studied mixtures are not 
pure, i.e. have other constituents which have not been taken into account in the analysis, such as 
dimethocaine, and that could interfere with the results predicted by mathematical models. 
 
Concentrations that produce 50% of the maximal effect in the MTT assay (EC50) were 
calculated by interpolation from the best-fit regression model for each product tested. A 
summary of the logit parameters for the best-fit regression model of each individual agent and 
mixture are in Table 12. These parameters were used to compute the predicted mixture effect 
curves shown in Figure 32. 
 
 
Table 12: Parameters derived from nonlinear fits of single agents and “legal highs” mixtures 
concentration-response data to the asymmetric logit function, in the MTT reduction assay, for 
primary hepatocytes. (n = 5; * P<0.05 for each product vs. MDMA)  
Compound 
 
Estimated parameters for the best-fit regression model of each 
individual agent 
 EC50 (mM) 
Fraction in the 
mixture 
Regression 
model 
θ1 θ2 θmax 
MDMA Logit -0.270 2.12 135 0.754 n/a 
Methylone 
4-MEC 
Pentedrone 
 “Bloom” 
Logit 
-0.647 
-1.78 
0.390 
1.40 
2.40 
1.64 
3.07 
3.42 
130 
296 
111 
110 
1.18* 
1.29* 
0.647 
0.346* 
0.439 
0.289 
0.272 
1 
4-MEC 
MDPV 
“Blow” 
Logit 
-1.78 
-0.332 
0.192 
1.64 
2.13 
4.39* 
296 
142 
108 
1.29* 
0.742 
0.840 
0.965 
0.0347 
1 
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2.6 “Bloom” and “Blow” are potent cytotoxic products 
 
The cathinones tested in this study share common metabolic pathways [80-83] and may 
compete with each other in these processes. From the analysis of the graphs in figure 32, there 
are synergistic/additive effects of the mixture components. Therefore, the “legal high” mixtures 
exhibit higher cytotoxicity than their individual components, wherein the “Bloom” and “Blow” 
have an EC50 of 0.346 mM and 0.840 mM, respectively. These values are significantly different 
(P< 0.0001), so we can conclude that “Bloom” is considerably more hepatotoxic than “Blow”.  
 
 
 
 
 
 
 
 
 
  
 
Figure 33 – Concentration-response curves obtained with the MTT reduction cytotoxicity assay for “legal 
highs” mixtures, in primary rat hepatocytes, after 48h incubation at 37 °C, and its comparison with pure 
MDMA in same conditions.  The grey lines show the EC50 and ECmax for each response curve and the 
dashed lines show the 95% CI belt of the fit. Data were normalized to negative (untreated) and positive 
(1% Triton X-100) controls and were obtained from five independent experiments run in triplicate. 
 
 
Once the synthetic cathinones holds structural similarities with MDMA, this compound 
was chosen to draw comparisons with “legal highs” mixtures at level of the hepatotoxic potency. 
If we establish a comparison between these real mixes and MDMA (figure 33), under the same 
conditions, we find that “Bloom” present EC50 value shifted to the left, i.e., lower, being more 
hepatotoxic than MDMA (P<0.05). Thus, in general, we can infer that a concentration of “Bloom” 
is potentially more hepatotoxic than the same concentration of pure ecstasy. However, the EC50 
values of “Blow” and MDMA are very similar (P>0.05), and therefore have a similar 
hepatotoxicity, though MDMA is more toxic to lower concentrations while the “Blow” is slightly 
more hepatotoxic to higher values. 
The additive effects of combination of amphetamines studies conducted by other authors 
[134] showed that the hepatotoxicity may be exacerbated by the combination of MDMA with 
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other amphetamines, which can be intentionally ingested or present in “ecstasy” pills as 
contaminants. 
In conclusion, the exposure of hepatocytes to “legal highs” mixtures definitely results in 
greater hepatotoxic effects expected. 
 
 
2.7 Primary rat hepatocytes are more sensitive to the cathinones effects than HepaRG cells 
 
Studies performed on HepaRG cells under the same conditions, revealed that all 
concentration-response curves are shifted to the right, showing higher EC50 values when 
compared to primary rat hepatocytes. A summary of the logit parameters for the best-fit 
regression model of each individual agent and mixture are presented for normothermic 
conditions in Table 13.  
 
 
 
 
 
 
 
 
 
 
 
Figure 34 – Concentration-response curves obtained with the MTT reduction cytotoxicity assay for “legal 
highs” mixtures and all individual agents used in study, in HepaRG cells after 48h incubation at 37 °C. 
Data were normalized to negative (untreated) and positive (1% Triton X-100) controls and were 
obtained from three independent experiments run in triplicate. 
 
 
In HepaRG cells, methylone remains the less toxic test compound (EC50 3.91 mM) and 
MDPV was determined to be the most hepatotoxic (EC50 0.975 mM) individual agent to the 
entire concentrations range. This result may be explained since recent studies show that, when 
compared to human hepatocytes, expression of CYP450 isoenzymes in HepaRG cells is generally 
lower, with the exception of a considerably higher expression of CYP3A4 and CYP7A1, as well as 
a relatively higher content of CYP2C19 mRNA content in this cell line [130]. Hereupon, HepaRG 
cells are metabolically less competent than primary human hepatocytes. It also explains the 
higher MDPV potency in all concentrations since this is mainly metabolized by CYP2C19 [81-82]. 
Some studies have also found that CYP1A2, CYP2A6 and CYP2D6 have significantly lower levels 
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of expression in HepaRG [123, 130], which may explain the lower hepatotoxic effects of methylone, 
as CYP2D6 is the primary isoenzyme involved in methylone metabolism. 
Although the HepaRG cells present low levels of expression to isoenzymes involved in the 
metabolism of synthetic cathinones studied, recent studies [135] show that HepaRG cells are 
metabolically more competent than other cell lines (such as HepG2), also presenting 
isoenzymes with a similar expression to human hepatocytes. 
 
 
Table 13: Parameters derived from nonlinear fits of single agents and “legal highs” mixtures 
concentration-response data to the asymmetric logit function, in the MTT reduction assay, in 
HepaRG cells. (n = 3; * P<0.05 for each product vs. MDMA) 
Compound 
 
Estimated parameters for the best-fit regression model of each 
individual agent 
 EC50 (mM) 
Regression 
model 
θ1 θ2 θmax 
MDMA 
Methylone 
4-MEC 
Pentedrone 
MDPV 
“Bloom” 
“Blow” 
Logit 
-7.947 
-8.64 
-7.90 
-0.84 
0.008 
0.27 
-2.827 
2.87 
3.71 
3.17 
4.07 
5.06 
6.13 
4.52 
33517 
31517 
26030 
104 
102.4 
99.1 
144.3 
3.16 
3.91 
3.32 
1.55 
0.975* 
0.911* 
3.06 
 
 
The effects of the individual compounds in the mixtures were also studied in HepaRG cells 
and “Bloom” (EC50 0.911 mM) remains more toxic than “Blow” (EC50 3.06 mM) or MDMA (EC50 
3.16 mM). In turn, “Blow”-induced cell death in HepaRG cells was closer to that observed with 
MDMA, resulting in overlapping concentration-response curves. In this assay, lower 
concentrations of MDPV showed no influence in the mixture, as similar effects were observed 
with “Blow” and 4-MEC, which may be due to the low metabolic capacity of the cell model. 
 
 
In synopsis, the present work clearly demonstrates that potentially harmful interactions 
among synthetic cathinones are expected when these drugs are taken concomitantly. Taking 
into account these results, evaluate combination effects of synthetic cathinones is extremely 
important from a toxicological point of view, since most of “legal highs” users, consciously or 
not, take a wide variety of cathinones and other substances on the same night. Understanding 
the impact of drug interactions can provide valuable information to explore the causes of 
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sudden lethal intoxications, as well as facilitate the diagnosis and treatment of non-fatal cases. A 
better understanding of these combined effects may have a considerable influence on public 
health, raising awareness of the potential for severe toxicity and therefore stimulating 
behavioral changes in consumers worldwide. 
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Conclusions of the chemical characterization part: 
 
 For the unequivocal identification of active principles of the new drugs, in the absence of 
standards, the GC-MS and NMR combination proved to be a powerful tool. 
 Products sold as “plant feeders” although labeled to contain ketones (hypotetical 
synthetic cathinones), also include substances belonging to other classes. However, the 
synthetic cathinones derivatives group is more representative. Caffeine is the most 
commonly compound detected in products. 
 The diversity in composition among these products is one of the greatest problems 
connected with the “legal highs” phenomenon. The consumers cannot be sure what they 
get. As has been shown, products with the same trade name have a different content and 
the same mixture is sold under different trade names. 
 Inconsistency in both qualitative and quantitative compositions could lead to serious 
consequences, because users are unware of active dose, time of duration and even the 
effects.  
 
 
Conclusions of the cytotoxicity studies: 
 
 All cathinones, individually or in mixtures, showed concentration-dependent decrease in 
cell viability, in both cell models.  
 Methylone and 4-MEC were less cytotoxic, while MDPV and pentedrone are the most 
cytotoxic cathinone derivatives, when compared with MDMA. 
 Results with HepaRG cells showed that they are less sensitive to cathinone effects than 
primary hepatocytes. This may be explained by the fact that HepaRG cells are 
metabolically less competent. 
 The “legal high” mixtures exhibit cytotoxity values higher than those of its individual 
components; the results show a synergistic effect for “Bloom” mixture and additive 
effect for “Blow” mixture.  
 “Bloom” is considerably more hepatotoxic compared to “Blow”. 
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